PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/31, 15/53, 15/55, 15/60, C12P 17/18, C12N 9/04, 9/16, 9/88, 1/21, C07K 14/24 // (C12N 1/21, C12R 1:19)

A2

(11) International Publication Number: **WO 99/58686**

(43) International Publication Date: 18 November 1999 (18.11.99)

(21) International Application Number: PCT/US99/10356

(22) International Filing Date: 12 May 1999 (12.05.99)

(30) Priority Data:
60/085,190 12 May 1998 (12.05.98) US

(71) Applicants *(for all designated States except US)*: E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). GENENCOR INTERNATIONAL, INC. [US/US]; 925 Page Mill Road, Palo Alto, CA 94304–1013 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: WHITED, Gregory, M. [US/US]; 304 South Road, Belmont, CA 94002 (US). BULTHUIS, Ben [NL/NL]; Einsteinweg 101, Postbus 251, NL–2300 AG Leiden (NL). TRIMBUR, Donald, E. [US/US]; 349 Orchard Avenue, Redwood City, CA 94601 (US). GATENBY, Anthony, A. [US/US]; 2309 Baynard Boulevard, Wilmington, DE 19802 (US).

(74) Agent: FLOYD, Linda, Axamethy; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AU, BR, CA, CN, ID, IL, JP, KR, MX, SG, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: METHOD FOR THE PRODUCTION OF 1,3–PROPANEDIOL BY RECOMBINANT ORGANISMS COMPRISING GENES FOR VITAMIN B12 TRANSPORT

(57) Abstract

Recombinant organisms are provided comprising genes encoding genes encoding glycerol dehydratase, 1,3–propanediol oxidoreductase, a gene encoding vitamin B_{12} receptor precursor (BtuB), a gene encoding vitamin B_{12} transport system permease protein (BtuC) and a gene encoding vitamin B_{12} transport ATP–binding protein (BtuD). The recombinant microorganism is contacted with a carbon substrate and 1,3–propanediol is isolated from the growth media.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

TITLE

METHOD FOR THE PRODUCTION OF 1,3-PROPANEDIOL BY RECOMBINANT ORGANISMS COMPRISING GENES FOR VITAMIN B_{12} TRANSPORT

FIELD OF INVENTION

The present invention relates to the field of molecular biology and the use of recombinant organisms for the production of 1,3-propanediol. More specifically it describes the expression of cloned genes that affect the intracellular transport of vitamin B_{12} in conjunction with genes that effectively convert a carbon substrate to 1,3-propanediol.

BACKGROUND

1,3-Propanediol is a monomer having utility in the production of polyester fibers and the manufacture of polyurethanes and cyclic compounds.

A variety of chemical routes to 1,3-propanediol are known. For example, 1,3-propanediol is prepared 1) from ethylene oxide over a catalyst in the presence of phosphine, water, carbon monoxide, hydrogen and an acid; 2) by the catalytic solution phase hydration of acrolein followed by reduction; or 3) from hydrocarbons such as glycerol, reacted in the presence of carbon monoxide and hydrogen over catalysts having atoms from Group VIII of the periodic table. Although it is possible to generate 1,3-propanediol by these methods, they are expensive and generate waste streams containing environmental pollutants.

It has been known for over a century that 1,3-propanediol can be produced from the fermentation of glycerol. Bacterial strains able to produce 1,3-propanediol have been found, for example, in the groups *Citrobacter*, *Clostridium*, *Enterobacter*, *Ilyobacter*, *Klebsiella*, *Lactobacillus*, and *Pelobacter*. In each case studied, glycerol is converted to 1,3-propanediol in a two-step, enzyme-catalyzed reaction sequence. In the first step, a dehydratase catalyzes the conversion of glycerol to 3-hydroxypropionaldehyde (3-HP) and water (Equation 1). In the second step, 3-HP is reduced to 1,3-propanediol by a NAD^+-linked oxidoreductase (Equation 2).

$$\text{Glycerol} \rightarrow \text{3-HP} + H_2O \qquad \text{(Equation 1)}$$

$$\text{3-HP} + NADH + H^+ \rightarrow \text{1,3-Propanediol} + NAD^+ \qquad \text{(Equation 2)}$$

The 1,3-propanediol is not metabolized further and, as a result, accumulates in high concentration in the media. The overall reaction consumes a reducing equivalent in the form of a cofactor, reduced β-nicotinamide adenine dinucleotide (NADH), which is oxidized to nicotinamide adenine dinucleotide (NAD^+).

The production of 1,3-propanediol from glycerol is generally performed under anaerobic conditions using glycerol as the sole carbon source and in the absence of other exogenous reducing equivalent acceptors. Under these conditions, in strains of *Citrobacter*, *Clostridium*, and *Klebsiella*, for example, a parallel pathway for glycerol operates which first involves oxidation of glycerol to dihydroxyacetone (DHA) by a NAD^+- (or $NADP^+$-) linked glycerol dehydrogenase (Equation 3). The DHA, following phosphorylation to dihydroxyacetone phosphate (DHAP) by a DHA kinase (Equation 4), becomes available for biosynthesis and for supporting ATP generation via, for example, glycolysis.

$$\text{Glycerol} + NAD^+ \rightarrow \text{DHA} + \text{NADH} + H^+ \qquad \text{(Equation 3)}$$

$$\text{DHA} + \text{ATP} \rightarrow \text{DHAP} + \text{ADP} \qquad \text{(Equation 4)}$$

In contrast to the 1,3-propanediol pathway, this pathway may provide carbon and energy to the cell and produces rather than consumes NADH.

In *Klebsiella pneumoniae* and *Citrobacter freundii*, the genes encoding the functionally linked activities of glycerol dehydratase (*dhaB*), 1,3-propanediol oxidoreductase (*dhaT*), glycerol dehydrogenase (*dhaD*), and dihydroxyacetone kinase (*dhaK*) are encompassed by the *dha* regulon. The *dha* regulons from *Citrobacter* and *Klebsiella* have been expressed in *Escherichia coli* and have been shown to convert glycerol to 1,3-propanediol.

The biological production of 1,3-propanediol requires glycerol as a substrate for a two step sequential reaction in which a dehydratase enzyme (typically a coenzyme B_{12}-dependent dehydratase) converts glycerol to an intermediate, 3-hydroxypropionaldehyde, which is then reduced to 1,3-propanediol by a NADH- (or NADPH) dependent oxidoreductase. These cofactor requirements are complex and necessitate the use of a whole cell catalyst for an industrial process incorporating this reaction sequence for the production of 1,3-propanediol. A process for the production of 1,3-propanediol from glycerol using an organism containing a coenzyme B_{12}-dependent diol dehydratase is described in US 5,633,362 (Nagarajan et al.). However, the process is not limited to the use of glycerol as feedstock. Glucose and other carbohydrates are suitable substrates and, recently, these substrates have been shown to be substrates for 1,3-propanediol production. Carbohydrates are converted to 1,3-propanediol using mixed microbial cultures where the carbohydrate is first fermented to glycerol by one microbial species and then converted to 1,3-propanediol by a second microbial species. US 5,599,689 (Haynie et al.). For reasons of simplicity

and economy, a single organism able to convert carbohydrates to 1,3-propanediol is preferred. Such an organism is described in US 5,686,279 (Laffend et al.).

Some bacteria, such as *Salmonella* or *Klebsiella*, are able to synthesize coenzyme B_{12} to enable a diol or glycerol dehydratase to operate, but other species must transport B_{12} from outside of the cell. The term "B_{12}" is used to refer collectively to coenzyme B_{12}; derivatives of coenzyme B_{12} where the upper axial 5'-deoxyadenosyl ligand is replaced with another ligand (for example, an aquo-, cyano- or methyl group); and the radical species, cob(II)alamin.

B_{12} transport into bacteria presents two major problems. First, the B_{12} molecule is too large for passage through outer membrane porins, thus requiring a specific outer membrane transport system. Second, owing to the scarcity of B_{12} in the environment, the outer membrane transport system must have a high affinity for B_{12} and move it into the periplasm for subsequent transport by another system across the inner membrane. For *E. coli*, which is unable to synthesize the corrin ring of B_{12}, an external supply of B_{12} is required for growth under certain conditions. These requirements may be modest; when a functional MetH is present ~25 B_{12} molecules (methylcobalamin) are required and ~500 coenzyme B_{12} molecules are needed for ethanolamine ammonia-lyase dependent growth.

Several proteins are required for the transport process. The 66 kDa outer membrane protein BtuB serves as the high affinity (Kd = 0.3 nM) receptor for adenosyl-, aquo-, cyano- and methyl cobalamins and the corresponding cobinamides. When grown in the absence of B_{12} or at low levels (<1 nM) ~ 200 copies of BtuB are present per cell. However, the growth of cells in media containing high levels of B_{12} (>0.1 uM) represses synthesis of BtuB, and even at levels of 5 nM uptake activities are repressed 80-90%. Unlike *Salmonella*, the *E. coli* BtuB is not repressed by aerobiosis. Transport into the periplasm requires the interaction of BtuB with a 26 kDa inner membrane protein TonB in an energy-dependent process that also requires co-transport of calcium. In fact, the high affinity binding of B_{12} to BtuB is calcium dependent and there is evidence for a reciprocal B_{12} dependent calcium binding site with a Kd for calcium of ~ 30 nM at pH 6.6 at saturating levels of B_{12}. This affinity for calcium decreases with decreasing pH. TonB uses proton motive force to drive a structural alteration needed for transport. In the absence of TonB, B_{12} penetrates the outer membrane with very low efficiency. TonB also energizes outer-membrane transport systems for iron, including the FepA and FhuA systems. Thus BtuB competes with these systems for TonB activity. In the absence of protein synthesis, the rate of B_{12} transport decreases with a half life of ~20 min and is attributable to a loss of TonB activity. Transfer of B_{12} from BtuB to the periplasmic binding protein is poorly

characterized and may involve a protein encoded by the *btuF* locus, at least in *Salmonella*.

Transport across the inner membrane is mediated by the BtuC and BtuD proteins encoded by the *btuCED* operon. BtuC and BtuD resemble transport proteins requiring a periplasmic binding protein, and BtuD has an ATP binding site. Mutant phenotypes of these two genes are corrected by a modest increase in external B_{12}, and it is thought that the BtuB/TonB system concentrates B_{12} in the periplasm and fortuitous transport of B_{12} is thus facilitated into the cytoplasm. BtuE may not be involved in transport and its function is unknown. The *btuCED* operon appears to be expressed constitutively and is not regulated by the presence of B_{12} in the growth medium.

The transport pathway can be summarized as an initial binding of B_{12} to the outer membrane protein BtuB, followed by interaction with the inner membrane protein TonB and the energy-dependent translocation and binding to periplasmic BtuF, and finally transfer to the inner membrane proteins BtuCD and translocation to the cytoplasm.

An important control mechanism for B_{12} transport is the influence of coenzyme B_{12} on the levels of the outer membrane protein BtuB. The formation of cellular coenzyme B_{12} results from the activity of ATP:corrinoid adenosyltransferase, encoded by the *btuR* gene. As noted above, the presence of B_{12} in media results in a reduction in BtuB function, but it is important to emphasize that this direct repression is observed only with coenzyme B_{12} and not with coenzyme B_{12} precursors, as seen by the addition of various B_{12} molecules to a *btuR*-defective strain. Coenzyme B_{12} precursors supplied in the media may cause repression resulting from its conversion into coenzyme B_{12}. Control appears to alter continuation of message synthesis rather than initiation, so the use of foreign promoters for *btuB* expression does not necessarily afford protection from regulation by coenzyme B_{12}. An unusual feature of *btuB* regulation is that repression seems to be as effective when the *btuB* gene is carried on a multicopy plasmid as when in a single copy. This apparent lack of titration by excess copies of the target sequences suggests a large excess of the repressor (coenzyme B_{12}) in the cell.

By gene fusion studies it appears that both transcriptional and translational control applies to *btuB* expression and, considered together, these various features suggest a mechanism in which a direct interaction occurs between coenzyme B_{12} and the mRNA leader. This interaction may induce mRNA folding to stabilize the hairpin thereby blocking ribosome access to the translational start. The requirement for a substantial portion of the *btuB* transcript in control of its own expression and regulation suggests that post-transcriptional events involving the

leader and *btuB* coding region influence both transcriptional read through and translation initiation. Involvement of transcribed regions in regulation has been documented for attenuation control in amino acid biosynthetic pathways, but the unusual features of *btuB* regulation are that important regulatory sites are located within the *btuB* coding sequence and that this regulation affects both transcription and translation.

The problem to be solved by the present invention is how to biologically produce 1,3-propanediol by means of a single recombinant organism containing a coenzyme B_{12}-dependent dehydratase enzyme enhancing the availability of coenzyme B_{12} to the enzyme by the presence of foreign genes encoding activities responsible for B_{12} transport.

SUMMARY OF THE INVENTION

Applicants have solved the stated problem by providing a single recombinant organism capable of the dehydratase-mediated bioconversion of a fermentable carbon source directly to 1,3-propanediol, where coenzyme B_{12} availability to the enzyme is enhanced by the presence of B_{12} transport genes. Preferred substrates are glucose and glycerol from a larger set of substrates including fermentable carbohydrates, single carbon substrates and mixtures thereof.

The present invention provides a process for the bio-production of 1,3-propanediol comprising: (i) contacting a transformed host cell with at least one fermentable carbon source and an effective amount of vitamin B_{12} whereby 1,3-propanediol is produced, the transformed host cell comprising: (a) at least one copy of a gene encoding a protein having a dehydratase activity; (b) at least one copy of a gene encoding a protein having an oxidoreductase activity; (c) at least one copy of a gene encoding a vitamin B_{12} receptor precursor protein; (d) at least one copy of a gene encoding a vitamin B_{12} transport system permease protein; and (e) at least one copy of a gene encoding vitamin B_{12} transport ATP- or GTP-binding protein; wherein at least one of the genes of (c), (d) or (e) is introduced into the host cell, and (ii) recovering the 1,3-propanediol produced from step (i). The effective amount of vitamin B_{12} is at a 0.1 to 10.0 fold molar ratio to the amount of dehydratase present.

The invention further provides a transformed host cell expressing a dehydratase enzyme containing (a) at least one copy of a gene encoding a protein having a dehydratase activity; (b) at least one copy of a gene having an oxidoreductase activity; (c) at least one copy of a gene encoding a vitamin B_{12} receptor precursor (BtuB); (d) at least one copy of a gene encoding a vitamin B_{12} transport system permease protein (BtuC); and (e) at least one copy of a gene

encoding vitamin B_{12} transport ATP-binding protein (BtuD), wherein at least one copy of the gene of (c), (d), or (e) is introduced into the host cell.

BRIEF DESCRIPTION OF SEQUENCE LISTING

Applicants have provided 25 sequences in conformity with Rules for the Standard Representation of Nucleotide and Amino Acid Sequences in Patent Applications (Annexes I and II to the Decision of the President of the EPO, published in Supplement No. 2 to OJ EPO, 12/1992), with 37 C.F.R. 1.821-1.825 and Appendices A and B (Requirements for Application Disclosures Containing Nucleotides and/or Amino Acid Sequences) with World Intellectual Property Organization (WIPO) Standard ST.25 (1998) and the sequence listing requirements of the EPO and PCT (Rules 5.2 and 49.5(a-bis), and Section 208 and Annex C of the Administrative Instructions). The Sequence Descriptions contain the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IYUB standards described in *Nucleic Acids Research 13*:3021-3030 (1985) and in the *Biochemical Journal 219 (No. 2)*:345-373 (1984) which are herein incorporated by reference.

SEQ ID NO:1 is the nucleotide sequence for an *E. coli btuB*, encoding the vitamin B_{12} receptor precursor protein.

SEQ ID NO:2 is the nucleotide sequence for a *Salmonella btuB*, encoding the vitamin B_{12} receptor precursor protein.

SEQ ID NO:3 is the nucleotide sequence for a *E. coli btuC*, encoding the vitamin B_{12} transport system permease protein.

SEQ ID NO:4 is the nucleotide sequence for a *E. coli btuD*, encoding the vitamin B_{12} transport ATP-binding protein.

SEQ ID NO:5 is the nucleotide sequence for a *E. coli btuE*, encoding the vitamin B_{12} transport periplasmic protein.

SEQ ID NO:6 is the nucleotide sequence for *dhaB1*, encoding the α subunit of the glycerol dehydratase enzyme.

SEQ ID NO:7 is the nucleotide sequence for *dhaB2*, encoding the β subunit of the glycerol dehydratase enzyme.

SEQ ID NO:8 is the nucleotide sequence for *dhaB3*, encoding the γ subunit of the glycerol dehydratase enzyme.

SEQ ID NO:9 is the nucleotide sequence for *dhaT*, encoding Klebsiella oxidoreductase enzyme.

SEQ ID NO:10 is the nucleotide sequence for PHK28-26 a 12.1 kb EcoRI-SalI fragment containing the dha operon.

SEQ ID NO:11 is the nucleotide sequence for a multiple cloning site and terminator sequence used in the construction of the expression vector pTacIQ.

SEQ ID NO:12-23 are primers used in the construction of expression vectors of the present invention.

SEQ ID NO:24 is the nucleotide sequence for an insert in pCL1920, used in the construction of the expression cassette for *dhaT* and *dhaB(1,2,3)*.

SEQ ID NO:25 is the nucleotide sequence for the glucose isomerase promoter sequence from *Streptomyces*.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method for biologically producing 1,3-propanediol from a fermentable carbon source in a single recombinant organism. The method incorporates a microorganism containing genes encoding glycerol dehydratase, 1,3-propanediol oxidoreductase, a gene encoding vitamin B_{12} receptor precursor(BtuB), a gene encoding vitamin B_{12} transport system permease protein(BtuC), and a gene encoding vitamin B_{12} transport ATP-binding protein (BtuD). The recombinant microorganism is contacted with a carbon substrate and 1,3-propanediol is isolated from the growth media.

The present method provides a rapid, inexpensive and environmentally responsible source of 1,3-propanediol monomer useful in the production of polyesters and other polymers.

The following definitions are to be used to interpret the claims and specification.

The terms "vitamin B_{12} receptor precursor", "BtuB" or "outer membrane vitamin B_{12} receptor protein" refer to the polypeptide located on the outer membrane of bacteria responsible for the transport of coenzyme B_{12}, cyanocobalamin, aquacobalamin, methycobalamin, and cobinamide from the culture media to the periplasmic space. For the purposes of the present invention BtuB includes, for example, the proteins encoded by the *btuB* genes of *Escherichia coli* (GenBank M10112) (SEQ ID NO:1), and of *Salmonella typhimurium* (GenBank M89481) (SEQ ID NO:2).

The terms "BtuC" or "vitamin B_{12} transport system permease protein" refer to the polypeptide located on the inner membrane of bacteria, that together with BtuD, transports vitamin B_{12} and coenzyme B_{12} from the periplasmic space to the cytoplasm. BtuC includes, for example, the polypeptide encoded by the *btuC* gene of *E. coli* (GenBank M14031) (SEQ ID NO:3).

The terms "BtuD" or "vitamin B_{12} transport ATP-binding protein" refer to the polypeptide located on the inner membrane of bacteria, that together with BtuC, transports vitamin B_{12} or coenzyme B_{12} from the periplasmic space to the cytoplasm. BtuD includes, for example, the polypeptide encoded by the *btuD* gene of *E. coli* (GenBank M14031) (SEQ ID NO:4).

The term "BtuE" refers to the polypeptide encoded by the *btuE* gene of *E. coli* (GenBank M14031) (SEQ ID NO:5) and is an auxiliary component of the transport system.

The terms "glycerol dehydratase" or "dehydratase enzyme" refer to the polypeptide(s) responsible for a coenzyme B_{12}-dependent enzyme activity that is capable of isomerizing or converting a glycerol molecule to the product 3-hydroxypropionaldehyde. For the purposes of the present invention, the dehydratase enzymes include a glycerol dehydratase (GenBank U09771, U30903) and a diol dehydratase (GenBank D45071) having preferred substrates of glycerol and 1,2-propanediol, respectively. Glycerol dehydratase of *K. pneumoniae* ATCC 25955 is encoded by the genes *dhaB1*, *dhaB2*, and *dhaB3* identified as SEQ ID NOS:6, 7, and 8 respectively. The *dhaB1*, *dhaB2* and *dhaB3* genes code for the α, β, and γ subunits of the glycerol dehydratase enzyme, respectively. Glycerol dehydratase and diol dehydratase enzymes are complexes (with an $\alpha_2\beta_2\gamma_2$ subunit composition) that bind coenzyme B_{12} with a 1:1 stoichiometry.

An "effective amount" of coenzyme B_{12} precursor (or vitamin B_{12}) will mean that coenzyme B_{12} precursor (or vitamin B_{12}) is present in the system at a molar ratio of between 0.1 and 10, relative to the dehydratase enzyme.

The terms "oxidoreductase" or "1,3-propanediol oxidoreductase" refer to the polypeptide(s) responsible for an enzyme activity that is capable of catalyzing the reduction of 3-hydroxypropionaldehyde to 1,3-propanediol. 1,3-Propanediol oxidoreductase includes, for example, the polypeptide encoded by the *dhaT* gene (GenBank U09771, U30903) and is identified as SEQ ID NO:9.

The terms "coenzyme B_{12}" and "adenosylcobalamin" are used interchangeably to mean 5'-deoxyadenosylcobalamin. Hydroxocobalamin is the derivative of coenzyme B_{12} where the upper axial 5'-deoxyadenosyl ligand is replaced with a hydroxy moiety. Aquacobalamin is the protonated form of hydroxocobalamin. Methylcobalamin is the derivative of coenzyme B_{12} where the upper axial 5'-deoxyadenosyl ligand is replaced with a methyl moiety. The term "cyanocobalamin" is used to refer to the derivative of coenzyme B_{12} where the upper axial 5'-deoxy'5'-adenosyl ligand is replaced with a cyano moiety. The terms "vitamin B_{12}" and "B_{12}" are used interchangeably to refer collectively to coenzyme B_{12}; derivatives of coenzyme B_{12} where the upper axial 5'-deoxyadenosyl ligand is replaced with another ligand, for example, an aquo-, cyano- or methyl group; and the radical species, cob(II)alamin. The term "coenzyme B_{12} precursor" refers to a derivation of coenzyme B_{12} where the upper axial 5'-deoxyadenosyl ligand is replaced. An "effective amount" of coenzyme B_{12} precursor will mean that coenzyme B_{12} precursor is present in the system at

approximately a 0.1- to 10.0-fold molar ratio to the amount of dehydratase enzyme present.

The terms "polypeptide" and "protein" are used interchangeably.

The terms "fermentable carbon substrate" and "fermentable carbon source" refer to a carbon source capable of being metabolized by host organisms of the present invention and particularly carbon sources selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, glycerol, dihydroxyacetone and one-carbon substrates or mixtures thereof.

The terms "host cell" or "host organism" refer to a microorganism capable of receiving foreign or heterologous genes or multiple copies of endogenous genes and of expressing those genes to produce an active gene product.

"Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" refers to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. "Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign" or "heterologous" gene refers to a gene not normally found in the host organism, but which is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

The terms "encoding" and "coding" refer to the process by which a gene, through the mechanisms of transcription and translation, produces an amino acid sequence. The process of encoding a specific amino acid sequence includes DNA sequences that may involve base changes that do not cause a change in the encoded amino acid, or which involve base changes which may alter one or more amino acids, but do not affect the functional properties of the protein encoded by the DNA sequence. It is therefore understood that the invention encompasses more than the specific exemplary sequences. Modifications to the sequence, such as deletions, insertions, or substitutions in the sequence which produce silent changes that do not substantially affect the functional properties of the resulting protein molecule are also contemplated. For example, alterations in the gene sequence which reflect the degeneracy of the genetic code, or which result in the production of a chemically equivalent amino acid at a given site, are

contemplated. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue (such as glycine), or a more hydrophobic residue (such as valine, leucine, or isoleucine). Similarly, changes which result in substitution of one negatively charged residue for another (such as aspartic acid for glutamic acid), or one positively charged residue for another (such as lysine for arginine), can also be expected to produce a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein. In some cases, it may in fact be desirable to make mutants of the sequence in order to study the effect of alteration on the biological activity of the protein. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity in the encoded products. Moreover, the skilled artisan recognizes that sequences encompassed by this invention are also defined by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 65 °C), with the sequences exemplified herein.

The term "expression" refers to the transcription and translation to gene product from a gene coding for the sequence of the gene product.

The terms "plasmid", "vector", and "cassette" refer to an extra chromosomal element often carrying genes which are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. "Transformation cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitate transformation of a particular host cell. "Expression cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in its host.

The terms "transformation" and "transfection" refer to the acquisition of new genes in a cell after the incorporation of nucleic acid. The acquired genes may be integrated into chromosomal DNA or introduced as extrachromosomal replicating sequences. The term "transformant" refers to the product of a transformation.

The term "genetically altered" refers to the process of changing hereditary material by transformation or mutation.

The present invention involves the construction of a production organism that incorporates the genetic machinery necessary to convert a fermentable carbon substrate to 1,3-propanediol, in conjunction with genes encoding enzymes needed for the intracellular transport of vitamin B_{12}. The genes involved in 1,3-propanediol production will include a dehydratase gene (typically a glycerol or diol dehydratase) and an oxidoreductase as well as other proteins expected to aid in the assembly or in maintaining the stability of the dehydratase enzyme. These genes may transgenes and introduced into the host cell, or may be endogenous. Genes responsible for the intracellular transport of vitamin B_{12} will include at least one gene encoding a vitamin B_{12} receptor precursor protein(BtuB), at least one gene encoding a gene encoding vitamin B_{12} transport system permease protein(BtuC) and at least one gene encoding vitamin B_{12} transport ATP-binding protein (BtuD). At least one of these genes will be a transgene and introduced into the production cell. The transformed production cell is then grown under appropriate conditions for the production of 1,3-propanediol.

Recombinant organisms containing the necessary genes that will encode the enzymatic pathway for the conversion of a carbon substrate to 1,3-propanediol may be constructed using techniques well known in the art. In the present invention genes encoding glycerol dehydratase (*dhaB*) and 1.3-propanediol oxidoreductase (*dhaT*) were isolated from a native host such as *Klebsiella*, and together with genes encoding BtuB (*btuB*), BtuC (*btuC*), BtuD (*btuD*), and BtuE (*btuE)* isolated from native hosts such as *E. coli* and *S. typhimurium* are used to transform host strains such as *E. coli* strain DH5α or FM5; *K. pneumoniae* strain ATCC 25955; *K. oxytoca* strain ATCC 8724 or M5a1, *S. cerevisiae* strain YPH499, *P. pastoris* strain GTS115, or *A. niger* strain FS1.

Rationale for *dhaB, dhaT*

The production of 1,3-propanediol from glucose can be accomplished by the following series of steps. This series is representative of a number of pathways known to those skilled in the art. Glucose is converted in a series of steps by enzymes of the glycolytic pathway to dihydroxyacetone phosphate (DHAP) and 3-phosphoglyceraldehyde (3-PG). Glycerol is then formed by either hydrolysis of DHAP to dihydroxyacetone (DHA) followed by reduction, or reduction of DHAP to glycerol 3-phosphate (G3P) followed by hydrolysis. The hydrolysis step can be catalyzed by any number of cellular phosphatases which are known to be non-specific with respect to their substrates or the activity can be introduced into the host by recombination. The reduction step can be catalyzed by a NAD^+ (or $NADP^+$) linked host enzyme or the activity can be introduced into the host by recombination. It is notable that the *dha* regulon contains a glycerol

dehydrogenase (E.C. 1.1.1.6) which catalyzes the reversible reaction of Equation 3.

$$\text{Glycerol} \rightarrow \text{3-HP} + H_2O \quad \text{(Equation 1)}$$

$$\text{3-HP} + NADH + H^+ \rightarrow \text{1,3-Propanediol} + NAD^+ \quad \text{(Equation 2)}$$

$$\text{Glycerol} + NAD^+ \rightarrow \text{DHA} + NADH + H^+ \quad \text{(Equation 3)}$$

Glycerol is converted to 1,3-propanediol via the intermediate 3-hydroxy-propionaldehye (3-HP) as has been described in detail above. The intermediate 3-HP is produced from glycerol, Equation 1, by a dehydratase enzyme which can be encoded by the host or can introduced into the host by recombination. This dehydratase can be glycerol dehydratase (E.C. 4.2.1.30), diol dehydratase (E.C. 4.2.1.28) or any other enzyme able to catalyze this transformation. Glycerol dehydratase, but not diol dehydratase, is encoded by the *dha* regulon. 1,3-Propanediol is produced from 3-HP, Equation 2, by a NAD^+- (or $NADP^+$) linked host enzyme or the activity can introduced into the host by recombination. This final reaction in the production of 1,3-propanediol can be catalyzed by 1,3-propanediol dehydrogenase (E.C. 1.1.1.202) or other alcohol dehydrogenases.

The *dha* regulon is comprised of several functional elements including *dhaK* encoding dihydroxyacetone kinase, *dhaD* encoding glycerol dehydrogenase, *dhaR* encoding a regulatory protein, *dhaT* encoding 1,3-propanediol oxidoreductase as well as *dhaB1*, *dhaB2*, and *dhaB3* encoding the α, β and γ subunits of the enzyme, respectively. Additionally, gene products designated as protein X, protein 1, protein 2, and protein 3 (corresponding to *dhaBX*, orfY, orfX, and orfW, respectively) are encoded within the *dha* regulon. While the precise functions of these gene products are not well characterized, the genes are linked to glycerol dehydratase (*dhaB*) or 1,3-propanediol oxidoreductase (*dhaT*) and are known to be useful for the production of 1,3-propanediol. Coenzyme B_{12} that is bound to glycerol dehydratase occasionally undergoes irreversible cleavage to form an inactive modified coenzyme which is tightly bound to the dehydratase. Reactivation of the enzyme occurs by exchange of the bound, modified coenzyme with free, intact coenzyme B_{12}. Protein X and at least one other of protein 1, protein 2, and protein 3 are involved in the exchange process. (See USSN 08/969,683). In the separate diol dehydratase system, genes designated as *ddrA* and *ddrB*, corresponding to the genes encoding protein X and protein 2, respectively, are described to be involved in the exchange process. Mori et al., *J. Biol. Chem.* 272, 32034-32041 (1997).

It is contemplated that glycerol-3-phosphate dehydrogenase and glycerol-3-phosphatase may be particularly effective in the conversion of glucose

to glycerol, required for the production of 1,3-propanediol. The term "glycerol-3-phosphate dehydrogenase" refers to a polypeptide responsible for an enzyme activity that catalyzes the conversion of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P). *In vivo* G3PDH may be NADH, NADPH, or FAD-dependent. The NADH-dependent enzyme (EC 1.1.1.8) is encoded, for example, by several genes including GPD1 (GenBank Z74071x2), or GPD2 (GenBank Z35169x1), or GPD3 (GenBank G984182), or DAR1 (GenBank Z74071x2). The NADPH-dependent enzyme (EC 1.1.1.94) is encoded by *gpsA* (GenBank U321643, (cds 197911-196892) G466746 and L45246). The FAD-dependent enzyme (EC 1.1.99.5) is encoded by GUT2 (GenBank Z47047x23), or glpD (GenBank G147838), or glpABC (GenBank M20938). The term "glycerol-3-phosphatase" refers to a polypeptide responsible for an enzyme activity that catalyzes the conversion of glycerol-3-phosphate and water to glycerol and inorganic phosphate. Glycerol-3-phosphatase is encoded, for example, by GPP1 (GenBank Z47047x125), or GPP2 (GenBank U18813x11).

Gene Isolation

Methods of obtaining desired genes from a bacterial genome are common and well known in the art of molecular biology. For example, if the sequence of the gene is known, suitable genomic libraries may be created by restriction endonuclease digestion and may be screened with probes complementary to the desired gene sequence. Once the sequence is isolated, the DNA may be amplified using standard primer directed amplification methods such as polymerase chain reaction (PCR) (US 4,683,202) to obtain amounts of DNA suitable for transformation using appropriate vectors.

Alternatively, cosmid libraries may be created where large segments of genomic DNA (35-45 kb) may be packaged into vectors and used to transform appropriate hosts. Cosmid vectors are unique in being able to accommodate large quantities of DNA. Generally, cosmid vectors have at least one copy of the *cos* DNA sequence which is needed for packaging and subsequent circularization of the foreign DNA. In addition to the *cos* sequence these vectors will also contain an origin of replication such as ColE1 and drug resistance markers such as a gene resistant to ampicillin or neomycin. Methods of using cosmid vectors for the transformation of suitable bacterial hosts are well described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989).

Typically to clone cosmids, foreign DNA is isolated and ligated, using the appropriate restriction endonucleases, adjacent to the *cos* region of the cosmid vector. Cosmid vectors containing the linearized foreign DNA are then reacted with a DNA packaging vehicle such as bacteriophage λ. During the packaging

process the *cos* sites are cleaved and the foreign DNA is packaged into the head portion of the bacterial viral particle. These particles are then used to transfect suitable host cells such as *E. coli*. Once injected into the cell, the foreign DNA circularizes under the influence of the *cos* sticky ends. In this manner large segments of foreign DNA can be introduced and expressed in recombinant host cells.

Isolation and cloning of genes encoding glycerol dehydratase (*dhaB*) and 1,3-propanediol oxidoreductase (*dhaT*)

Methods for the identification and isolation of *dhaB* and *dhaT* were done essentially as described in US 5,686,276 and hereby incorporated by reference. Cosmid vectors and cosmid transformation methods were used within the context of the present invention to clone large segments of genomic DNA from bacterial genera known to possess genes capable of processing glycerol to 1,3-propanediol. Two 1,3-propanediol positive transformants were analyzed and DNA sequencing revealed extensive homology to the glycerol dehydratase gene (*dhaB*) from *C. freundii*, demonstrating that these transformants contained DNA encoding the glycerol dehydratase gene. *dhaB* and *dhaT* were isolated and cloned into appropriate expression cassettes for co-expression in recombinant hosts with genes encoding B_{12} transport functions.

Although the instant invention utilizes the isolated genes from within a *Klebsiella* cosmid, alternate sources of dehydratase genes include, but are not limited to, *Citrobacter*, *Clostridia*, and *Salmonella*.

B_{12} Transport genes

Rationale for B_{12} transport genes

Adenosyl-cobalamin (coenzyme B_{12}) is an essential cofactor for glycerol dehydratase activity. The coenzyme is the most complex non-polymeric natural product known, and its synthesis *in vivo* is directed using the products of about 30 genes. Synthesis of coenzyme B_{12} is found in prokaryotes, some of which are able to synthesize the compound *de novo*, while others can perform partial reactions. *E. coli*, for example, cannot fabricate the corrin ring structure, but is able to catalyze the conversion of cobinamide to corrinoid and can introduce the 5'-deoxyadenosyl group.

B_{12} transport into *E. coli* may be a limiting factor for the production of a functional DhaB enzyme, in which case increased intracellular availability of coenzyme B_{12} would be required to optimize glycerol dehydratase activity (and, ultimately, 1,3-propanediol production). This may be achieved by increasing the rate of transport of B_{12} into the cell. Given the role of coenzyme B_{12} as a repressor of *btuB* expression, and the levels of coenzyme B_{12} required in fermentations, it is likely that B_{12} transport declines over time due to turnover or

dilution of BtuB from cell division. The available pool of free coenzyme B_{12} in the cell will be influenced by the rate of uptake, the relative affinities of BtuB mRNA and DhaB for coenzyme B_{12}, and the concentrations of the mRNA and DhaB. Since uptake is reduced when using B_{12} enriched media, an important factor determining whether the uptake mechanism is restored will be partitioning of coenzyme B_{12} between its regulatory role on btuB expression and DhaB enzyme. This presents an unusual problem of a desired cofactor (coenzyme B_{12}) being responsible for its own limitation. The use of media containing coenzyme B_{12} precursors in place of coenzyme B_{12} may alleviate the problem, but this will only be a temporary gain since the transported precursors will be converted to coenzyme B_{12} by the *btuR*-encoded adenosyltransferase. One way to circumvent this gene regulation problem is to uncouple BtuB synthesis from coenzyme B_{12} regulation. Amplification of *btuB* expression by cloning on multicopy plasmids leads to increased binding of B_{12} to membranes and increased rates of uptake, and if the *btuB* native promoter is replaced, will also uncouple synthesis of BtuB from coenzyme B_{12} regulation.

B_{12} transport into bacteria requires a specific transport system. Several proteins are required for this transport process. The 66 kDa outer membrane protein BtuB serves as a receptor for adenosyl-, aquo-, cyano- and methyl cobalamins and the corresponding cobinamides. Transport into the periplasm requires the interaction of BtuB with a 26 kDa inner membrane protein TonB in an energy-dependent process. Transport across the inner membrane is mediated by the BtuC and BtuD proteins encoded by the *btuCED* operon. BtuC and BtuD resemble transport proteins requiring a periplasmic binding protein, and BtuD has an ATP binding site. The transport pathway can be summarized as an initial binding of B_{12} to the outer membrane protein BtuB, followed by interaction with the inner membrane protein TonB and the energy-dependent translocation and binding to periplasmic BtuF (in *S. typhimurium*), and finally transfer to the inner membrane proteins BtuCD and translocation to the cytoplasm. Amplification of *btuBCED* expression by cloning on multicopy plasmids leads to increased binding of B_{12} to membranes and increased rates of uptake into cells.

Isolation and Expression of the B_{12} Transport Genes

Expression plasmids that could exist as replicating elements in *E. coli* were constructed for the four B_{12} transport genes, *btuB*, *btuC*, *btuD* and *btuE*. The four genes were isolated by PCR using gene-specific primers and *E. coli* chromosomal DNA. The four genes were assembled together on expression plasmids. All expression plasmids use a *trc* promoter for transcription and the native *btu* ribosome binding sites for translation. Each plasmid also contained either 1) a gene for β-lactamase for selection in *E. coli* on media containing ampicillin or 2) a

gene encoding chloramphenicol acetytransferase for selection on media containing chloramphenicol. Plasmid origins of replication are either ColE1 or p15A.

Host cells

Suitable host cells for the recombinant production 1,3-propanediol by the coexpression of a gene encoding a dehydratase enzyme and the genes responsible for intracellular B_{12} transport may be either prokaryotic or eukaryotic and will be limited only by their ability to express active enzymes. Preferred hosts will be those typically useful for production of 1,3-propanediol or glycerol such as *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces* and *Pseudomonas*. Most preferred in the present invention are *E. coli*, *Klebsiella* species, and *Saccharomyces* species.

E. coli, *Saccharomyces* species, and *Klebsiella* species are particularly preferred hosts. Strains of *Klebsiella pneumoniae* are known to produce 1,3-propanediol when grown on glycerol as the sole carbon. It is contemplated that *Klebsiella* can be genetically altered to produce 1,3-propanediol from monosaccharides, oligosaccharides, polysaccharides, or one-carbon substrates.

Vectors and expression cassettes

The present invention provides a variety of vectors and transformation and expression cassettes suitable for the cloning, transformation and expression of genes encoding a suitable dehydratase and genes effecting the intracellular transport of B_{12} to into a suitable host cell. Suitable vectors will be those which are compatible with the bacterium employed. Suitable vectors can be derived, for example, from a bacteria, a virus (such as bacteriophage T7 or a M-13 derived phage), a cosmid, a yeast, or a plant. Protocols for obtaining and using such vectors are known to those in the art. (Sambrook et al., Molecular Cloning: A Laboratory Manual - volumes 1,2,3 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, (1989)).

Typically, the vector or cassette contains sequences directing transcription and translation of the relevant gene, a selectable marker, and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene which harbors transcriptional initiation controls and a region 3' of the DNA fragment which controls transcriptional termination. It is most preferred when both control regions are derived from genes homologous to the transformed host cell although it is to be understood that such control regions need not be derived from the genes native to the specific species chosen as a production host.

Initiation control regions or promoters, which are useful to drive expression of the relevant genes of the present invention in the desired host cell, are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these genes is suitable for the present invention including but not limited to CYC1, HIS3, GAL1, GAL10, ADH1, PGK, PHO5, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TPI (useful for expression in *Saccharomyces*); AOX1 (useful for expression in *Pichia*); and lac, trp, λP_L, λP_R, T7, tac, and trc (useful for expression in *E. coli*).

Termination control regions may also be derived from various genes native to the preferred hosts. Optionally, a termination site may be unnecessary; however, it is most preferred if included.

For effective expression of the instant enzymes, DNA encoding the enzymes are linked operably through initiation codons to selected expression control regions such that expression results in the formation of the appropriate messenger RNA.

Transformation of suitable hosts and expression of genes for the production of 1,3-propanediol

Once suitable cassettes are constructed they are used to transform appropriate host cells. Introduction into the host cell of the cassette containing the genes responsible for intracellular B_{12} transport as well as glycerol dehydratase (*dhaB*), and 1,3-propanediol oxidoreductase (*dhaT*), either separately or together, may be accomplished by known procedures such as by transformation (e.g., using calcium-permeabilized cells, electroporation) or by transfection using a recombinant phage virus. (Sambrook et al., *supra*.)

In the present invention, *E. coli* FM5 containing the genes encoding glycerol dehydratase (*dhaB*), 1,3-propanediol oxidoreductase (*dhaT*), BtuB (*btuB*), BtuC (*btuC*), BtuD (*btuD*), and BtuE (*btuE*) is used to transport vitamin B_{12} or coenzyme B_{12} from the media into the cytoplasm to enable glycerol dehydratase to function.

Media and Carbon Substrates:

Fermentation media in the present invention must contain suitable carbon substrates. Suitable substrates may include but are not limited to glycerol, dihydroxyacetone, monosaccharides such as glucose and fructose, oligosaccharides such as lactose or sucrose, polysaccharides such as starch or cellulose, or mixtures thereof, and unpurified mixtures from renewable feedstocks such as cheese whey permeate, cornsteep liquor, sugar beet molasses, and barley malt. Additionally, the carbon substrate may also be one-carbon substrates (such as carbon dioxide or methanol) for which metabolic conversion into key biochemical intermediates has been demonstrated.

Glycerol production from single carbon sources (e.g., methanol, formaldehyde, or formate) has been reported in methylotrophic yeasts (Yamada et al., *Agric. Biol. Chem.*, 53(2) 541-543, (1989)) and in bacteria (Hunter et al., *Biochemistry*, 24, 4148-4155, (1985)). These organisms can assimilate single carbon compounds, ranging in oxidation state from methane to formate, and produce glycerol. The pathway of carbon assimilation can be through ribulose monophosphate, through serine, or through xylulose-monophosphate (Gottschalk, Bacterial Metabolism, Second Edition, Springer-Verlag: New York (1986)). The ribulose monophosphate pathway involves the condensation of formate with ribulose-5-phosphate to form a 6 carbon sugar that becomes fructose and eventually the three carbon product glyceraldehyde-3-phosphate. Likewise, the serine pathway assimilates the one-carbon compound into the glycolytic pathway via methylenetetrahydrofolate.

In addition to utilization of one and two carbon substrates, methylotrophic organisms are also known to utilize a number of other carbon-containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity. For example, methylotrophic yeast are known to utilize the carbon from methylamine to form trehalose or glycerol (Bellion et al., *Microb. Growth C1 Compd.*, [Int. Symp.], 7th (1993), 415-32. Editor(s): Murrell, J. Collin; Kelly, Don P. Publisher: Intercept, Andover, UK). Similarly, various species of *Candida* will metabolize alanine or oleic acid (Sulter et al., *Arch. Microbiol.*, 153(5), 485-9 (1990)). Accordingly, the source of carbon utilized in the present invention may encompass a wide variety of carbon-containing substrates and will only be limited by the requirements of the host organism.

Although it is contemplated that all of the above-mentioned carbon substrates and mixtures thereof are suitable in the present invention, preferred carbon substrates are glycerol, dihydroxyacetone, monosaccharides, oligosaccharides, polysaccharides, and one-carbon substrates. More preferred are sugars such as glucose, fructose, sucrose and single carbon substrates such as methanol and carbon dioxide. Most preferred is glucose.

In addition to an appropriate carbon source, fermentation media must contain suitable minerals, salts, cofactors, buffers and other components, known to those skilled in the art, suitable for the growth of the cultures and promotion of the enzymatic pathway necessary for glycerol production. Particular attention is given to Co(II) salts and coenzyme B_{12} precursors. For example, *E. coli* and eukaryotes are unable to synthesize coenzyme B_{12} *de novo* but are able to utilize coenzyme B_{12} precursors. Preferred coenzyme B_{12} precursors are cyanocobalamin and hydroxocobalamin. It is desirable that the amount of

coenzyme B_{12} inside the host cell be approximately equal in molar concentration to the amount of dehydratase enzyme.

Culture Conditions:

Typically, cells are grown at 30 °C in appropriate media. Preferred growth media in the present invention are common commercially prepared media such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth or Yeast Malt Extract (YM) broth. Other defined or synthetic growth media may also be used and the appropriate medium for growth of the particular microorganism will be known by someone skilled in the art of microbiology or fermentation science. The use of agents known to modulate catabolite repression directly or indirectly, e.g., cyclic adenosine 3':5'-monophosphate, may also be incorporated into the reaction media. Similarly, the use of agents known to modulate enzymatic activities (e.g., sulphites, bisulphites and alkalis) that lead to enhancement of glycerol production may be used in conjunction with or as an alternative to genetic manipulations.

Suitable pH ranges for the fermentation are between pH 5.0 to pH 9.0, where pH 6.0 to pH 8.0 is preferred as the range for the initial condition.

Reactions may be performed under aerobic or anaerobic conditions where anaerobic or microaerobic conditions are preferred.

Fermentations:

The present invention may be practiced using either batch, Fed-Batch, or continuous processes and that any known mode of fermentation would be suitable. Additionally, it is contemplated that cells may be immobilized on a substrate as whole cell catalysts and subjected to fermentation conditions for 1,3-propanediol production.

The present process is exemplified herein as a batch method of fermentation. A classical batch fermentation is a closed system where the composition of the media is set at the beginning of the fermentation and not subject to artificial alterations during the fermentation. Thus, at the beginning of the fermentation the media is inoculated with the desired organism or organisms and fermentation is permitted to occur adding nothing to the system. Typically, however, a batch fermentation is "batch" with respect to the addition of the carbon source and attempts are often made at controlling factors such as pH and oxygen concentration. The metabolite and biomass compositions of the batch system change constantly up to the time the fermentation is stopped. Within batch cultures cells moderate through a static lag phase to a high growth log phase and finally to a stationary phase where growth rate is diminished or halted. If untreated, cells in the stationary phase will eventually die. Cells in log phase generally are responsible for the bulk of production of end product or intermediate.

A variation on the standard batch system is the Fed-Batch fermentation system which is also suitable in the present invention. In this variation of a typical batch system, the substrate is added in increments as the fermentation progresses. Fed-Batch systems are useful when catabolite repression is apt to inhibit the metabolism of the cells and where it is desirable to have limited amounts of substrate in the media. Measurement of the actual substrate concentration in Fed-Batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen, and the partial pressure of waste gases such as CO_2. Batch and Fed-Batch fermentations are common and well known in the art and examples may be found in Brock, *infra*.

The method would also be adaptable to continuous fermentation methods. Continuous fermentation is an open system where a defined fermentation media is added continuously to a bioreactor and an equal amount of conditioned media is removed simultaneously for processing. Continuous fermentation generally maintains the cultures at a constant high density where cells are primarily in log phase growth.

Continuous fermentation allows for the modulation of one factor or any number of factors that affect cell growth or end product concentration. For example, one method will maintain a limiting nutrient such as the carbon source or nitrogen level at a fixed rate and allow all other parameters to moderate. In other systems a number of factors affecting growth can be altered continuously while the cell concentration, measured by media turbidity, is kept constant. Continuous systems strive to maintain steady state growth conditions and thus the cell loss due to media being drawn off must be balanced against the cell growth rate in the fermentation. Methods of modulating nutrients and growth factors for continuous fermentation processes as well as techniques for maximizing the rate of product formation are well known in the art of industrial microbiology. A variety of methods are detailed by Brock, *infra*.

Identification and purification of 1,3-propanediol:

Methods for the purification of 1,3-propanediol from fermentation media are known in the art. For example, propanediols can be obtained from cell media by subjecting the reaction mixture to extraction with an organic solvent, distillation, and column chromatography (US 5,356,812). A particularly good organic solvent for this process is cyclohexane (US 5,008,473).

1,3-Propanediol may be identified directly by submitting the media to high pressure liquid chromatography (HPLC) analysis. Preferred in the present invention is a method where fermentation media are analyzed on an analytical ion

exchange column using a mobile phase of 0.01 N sulfuric acid in an isocratic fashion.

The present invention is further defined in the following Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

EXAMPLES

GENERAL METHODS

Procedures for phosphorylations, ligations, and transformations are well known in the art. Techniques suitable for use in the following examples may be found in Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989).

Materials and methods suitable for the maintenance and growth of bacterial cultures are well known in the art. Techniques suitable for use in the following examples may be found as set out in Manual of Methods for General Bacteriology (Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, eds), American Society for Microbiology, Washington, DC. (1994)) or by Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition, Sinauer Associates, Inc., Sunderland, MA (1989). All reagents and materials used for the growth and maintenance of bacterial cells were obtained from Aldrich Chemicals (Milwaukee, WI), DIFCO Laboratories (Detroit, MI), GIBCO/BRL (Gaithersburg, MD), or Sigma Chemical Company (St. Louis, MO) unless otherwise specified.

The meaning of abbreviations is as follows: "h" means hour(s), "min" means minute(s), "sec" means second(s), "d" means day(s), "mL" means milliliters, "L" means liters.

Isolation and Identification 1,3-propanediol

The conversion of glycerol to 1,3-propanediol was monitored by HPLC. Analyses were performed using standard techniques and materials available to one skilled in the art of chromatography. One suitable method utilized a Waters Maxima 820 HPLC system using UV (210 nm) and RI detection. Samples were injected onto a Shodex SH-1011 column (8 mm x 300 mm, purchased from Waters, Milford, MA) equipped with a Shodex SH-1011P precolumn (6 mm x 50 mm), temperature controlled at 50 °C, using 0.01 N H_2SO_4 as mobile phase at a flow rate of 0.5 mL/min. When quantitative analysis was desired, samples were prepared with a known amount of trimethylacetic acid as external standard.

Typically, the retention times of glycerol (RI detection), 1,3-propanediol (RI detection), and trimethylacetic acid (UV and RI detection) were 20.67 min, 26.08 min, and 35.03 min, respectively.

Production of 1,3-propanediol was confirmed by GC/MS. Analyses were performed using standard techniques and materials available to one of skill in the art of GC/MS. One suitable method utilized a Hewlett Packard 5890 Series II gas chromatograph coupled to a Hewlett Packard 5971 Series mass selective detector (EI) and a HP-INNOWax column (30 m length, 0.25 mm i.d., 0.25 micron film thickness). The retention time and mass spectrum of 1,3-propanediol generated were compared to that of authentic 1,3-propanediol (*m/e*: 57, 58).

An alternative method for GC/MS involved derivatization of the sample. To 1.0 mL of sample (e.g., culture supernatant) was added 30 uL of concentrated (70% v/v) perchloric acid. After mixing, the sample was frozen and lyophilized. A 1:1 mixture of bis(trimethylsilyl)trifluoroacetamide:pyridine (300 uL) was added to the lyophilized material, mixed vigorously and placed at 65 °C for one h. The sample was clarified of insoluble material by centrifugation. The resulting liquid was partitioned into two phases, the upper of which was used for analysis. The sample was chromatographed on a DB-5 column (48 m, 0.25 mm I.D., 0.25 um film thickness; from J&W Scientific) and the retention time and mass spectrum of the 1,3-propanediol derivative obtained from culture supernatants were compared to that obtained from authentic standards. The mass spectrum of TMS-derivatized 1,3-propanediol contains the characteristic ions of 205, 177, 130 and 115 AMU.

Identification of vitamin or coenzyme B_{12}

Cell free samples were run on HPLC for coenzyme B_{12} and cyanocobalamin (cyanocobalamin) quantification. Cobalamin quantification was achieved via first comparing peak area ratios at 278 nm and 361 nm with standards, and then applying peak areas to standard curves of the cobalamins.

HPLC Method

Column:	Supelcosil LC-18-DB, 25 cm x 4.6 mm (Supelco, Inc., Bellefonte, PA)
	Supelcosil LC-18-DB Precolumn kit
Column Temp:	Ambient
Sample Chamber:	Dark, 5 °C
Detection:	254 nm, and 360 nm
Injection Volume:	25 uL
Mobile Phase A:	8.95 g Sodium acetate.$3H_2O$
	5.88 mL 1.0 M Tetrabutylammonium hydroxide (TBAH)
	4 L MQ H_2O

pH to 4.6 with glacial acetic acid
Add 210 mL of Mobile Phase B (below)

Mobile Phase B: 4 L MeOH
5.88 mL TBAH
0.89 mL Glacial acetic acid

Gradient:	Time(minutes)	Flow mL/min	A%	B%
	0	1.0	100	0
	3	1.0	75	25
	9	1.0	60	40
	11	1.0	0	100
	13	1.0	0	100
	15	1.0	100	0
	15.5	0.1	100	0

Isolation and cloning of genes encoding glycerol dehydratase (*dhaB*) and 1,3-propanediol oxidoreductase (*dhaT*)

Methods for the identification and isolation of *dhaB* and *dhaT* were done essentially as described in US 5,686,276, hereby incorporated by reference. Cosmid vectors and cosmid transformation methods were used within the context of the present invention to clone large segments of genomic DNA from bacterial genera known to possess genes capable of processing glycerol to 1,3-propanediol. Specifically, genomic DNA from *K. pneumoniae* ATCC 25955 was isolated by methods well known in the art and digested with the restriction enzyme Sau3A for insertion into a cosmid vector Supercos 1 and packaged using GigapackII packaging extracts. Following construction of the vector *E. coli* XL1-Blue MR cells were transformed with the cosmid DNA. Transformants were screened for the ability to convert glycerol to 1,3-propanediol by growing the cells in the presence of glycerol and analyzing the media for 1,3-propanediol formation.

Two of the 1,3-propanediol positive transformants were analyzed and the cosmids were named pKP1 and pKP2. DNA sequencing revealed extensive homology to the glycerol dehydratase gene (*dhaB*) from *C. freundii*, demonstrating that these transformants contained DNA encoding the glycerol dehydratase gene.

A 12.1 kb EcoRI-SalI fragment from pKP1, subcloned into pIBI31 (IBI Biosystem, New Haven, CN), was sequenced and termed pHK28-26 (SEQ ID NO:10). Sequencing revealed the loci of the relevant open reading frames of the *dha* operon encoding glycerol dehydratase and genes necessary for regulation. Referring to SEQ ID NO:10, a fragment of the open reading frame for *dhaK* (encoding dihydroxyacetone kinase) is found at bases 1-399; the open reading frame *dhaD* (encoding glycerol dehydrogenase) is found at bases 983-2107; the

open reading frame *dhaR* (encoding the repressor) is found at bases 2209-4134; the open reading frame *dhaT* (encoding 1,3-propanediol oxidoreductase) is found at bases 5017-6180; the open reading frame *dhaB1* (encoding the α subunit glycerol dehydratase) is found at bases 7044-8711; the open reading frame *dhaB2* (encoding the β subunit glycerol dehydratase) is found at bases 8724-9308; the open reading frame *dhaB3* (encoding the γ subunit glycerol dehydratase) is found at bases 9311-9736; and the open reading frame *dhaBX* (encoding a protein of unknown function) is found at bases 9749-11572. Additionally, the open reading frame orfY (encoding a protein of unknown function) is found at bases 6202-6630; the open reading frame orfX (encoding a protein of unknown function) is found at bases 4643-4996, and the open reading frame orfW (encoding a protein of unknown function) is found at bases 4112-4642.

Construction of General Purpose Expression Plasmids For Use In Transformation of *Escherichia coli*

Construction of expression vector pTacIQ

The *E. coli* expression vector pTacIQ was prepared by inserting lacIq gene (Farabaugh, (1978), *Nature* 274 (5673) 765-769) and tac promoter (Amann et al., (1983), *Gene* 25, 167-178) into the restriction endonuclease site EcoRI of pBR322 (Sutcliffe, (1979), *Cold Spring Harb. Symp. Quant. Biol.* 43, 77-90). A multiple cloning site and terminator sequence (SEQ ID NO:11) replaces the pBR322 sequence from EcoRI to SphI.

Subcloning the glycerol dehydratase genes (*dhaB1, 2, 3, X*)

The open reading frame for the *dhaB3* gene was amplified from pHK 28-26 by PCR using primers (SEQ ID NO:12 and SEQ ID NO:13) incorporating an EcoRI site at the 5' end and a XbaI site at the 3' end. The product was subcloned into pLitmus29 (New England Biolab, Inc., Beverly, MA) to generate the plasmid pDHAB3 containing *dhaB3*.

The region containing the entire coding region for *dhaB1*, *dhaB2*, *dhaB3* and *dhaBX* of the *dhaB* operon from pHK28-26 was cloned into pBluescriptIIKS+ (Stratagene, La Jolla, CA) using the restriction enzymes KpnI and EcoRI to create the plasmid pM7.

The *dhaBX* gene was removed by digesting plasmid pM7 with ApaI and XbaI, purifying the 5.9 kb fragment and ligating it with the 325-bp ApaI-XbaI fragment from plasmid pDHAB3 to create pM11 containing dhaB1, dhaB2 and dhaB3.

The open reading frame for the *dhaB1* gene was amplified from pHK28-26 by PCR using primers (SEQ ID NO:14 and SEQ ID NO:15) incorporating a HindIII site and a consensus ribosome binding site at the 5' end and a XbaI site at

the 3' end. The product was subcloned into pLitmus28 (New England Biolab, Inc.) to generate the plasmid pDT1 containing *dhaB1*.

A NotI-XbaI fragment from pM11 containing part of the dhaB1 gene, the *dhaB2* gene and the *dhaB3* gene was inserted into pDT1 to create the *dhaB* expression plasmid, pDT2. The HindIII-XbaI fragment containing the *dhaB(1,2,3)* genes from pDT2 was inserted into pTacIQ to create pDT3.

Subcloning the 1,3-propanediol dehydrogenase gene (*dhaT*)

The KpnI-SacI fragment of pHK28-26, containing the 1,3-propanediol dehydrogenase (*dhaT*) gene, was subcloned into pBluescriptII KS+ creating plasmid pAH1. The *dhaT* gene was amplified by PCR from pAH1 as template DNA and synthetic primers (SEQ ID NO:16 with SEQ ID NO:17) incorporating an XbaI site at the 5' end and a BamHI site at the 3' end. The product was subcloned into pCR-Script (Stratagene) at the SrfI site to generate the plasmids pAH4 and pAH5 containing *dhaT*. The plasmid pAH4 contains the *dhaT* gene in the right orientation for expression from the lac promoter in pCR-Script and pAH5 contains *dhaT* gene in the opposite orientation. The XbaI-BamHI fragment from pAH4 containing the *dhaT* gene was inserted into pTacIQ to generate plasmid pAH8. The HindII-BamHI fragment from pAH8 containing the RBS and *dhaT* gene was inserted into pBluescriptIIKS+ to create pAH11.

Construction of an expression cassette for *dhaT* and *dhaB(1, 2, 3)*

An expression cassette for *dhaT* and *dhaB(1, 2, 3)* was assembled from the individual *dhaB(1, 2, 3)* and *dhaT* subclones described previously using standard molecular biology methods. A SpeI-SacI fragment containing the *dhaB(1, 2, 3)* genes from pDT3 was inserted into pAH11 at the SpeI-SacI sites to create pAH24. A SalI-XbaI linker (SEQ ID NO:22 and SEQ ID NO:23) was inserted into pAH5 which was digested with the restriction enzymes SalI-XbaI to create pDT16. The linker destroys the XbaI site. The 1 kb SalI-MluI fragment from pDT16 was then inserted into pAH24 replacing the existing SalI-MluI fragment to create pDT18. pDT21 was constructed by inserting the SalI-NotI fragment from pDT18 and the NotI-XbaI fragment from pM7 into pCL1920 (SEQ ID NO:24). The glucose isomerase promoter sequence from *Streptomyces* (SEQ ID NO:25) was cloned by PCR and inserted into EcoRI-HinDIII sites of pLitmus28 to construct pDT5. pCL1925 was constructed by inserting EcoRI-PvuII fragment of pDT5 into the EcoRI-PvuI site of pCL1920. pDT24 was constructed by cloning the HinDIII-MluII fragment of pDT21 and the MluI-XbaI fragment of pDT21 into the HinDIII-XbaI sites of pCL1925.

EXAMPLE 1

Construction Of Expression Cassette For B_{12} Transport Genes

Expression plasmids that could exist as replicating elements were constructed for the four B_{12} transport genes, *btuB*, *btuC*, *btuD*, and *btuE*. All expression plasmids use a *trc* promoter for transcription Each plasmid also contained either a gene for β-lactamase for selection in *E. coli* on media containing ampicillin, or a gene encoding chloramphenicol acetytransferase for selection on media containing chloramphenicol. Plasmid origins of replication are either ColE1 or p15A.

The *btuB* gene was amplified from *E. coli* chromosomal DNA by PCR using primers (SEQ ID NO:18 with SEQ ID NO:19) which adds an NcoI site at the 5' end and a BamHI site at the 3' end. Reaction mixture contained 10 mM Tris pH 8.3, 50 mM KCl, 1.5 mM $MgCl_2$, 0.0001% gelatin, 200 μM dATP, 200 μM dCTP, 200 μM dGTP, 200 μM dTTP, 1 μM each primer, 1-10 ng target DNA, 25 units/mL Amplitaq™ DNA polymerase (Perkin-Elmer Cetus, Norwalk CT). PCR parameters were 1 min at 94 °C, 1 min at 52 °C, 2 min at 72 °C, 25 cycles. The 1905 bp PCR product was cloned between the NcoI and BamHI sites of plasmid pTrc99A (Pharmacia, Piscataway, NJ) to generate the plasmid pBtuB1. Plasmid pBtuB1 has a ColE1 origin of replication, ampicillin resistance a *lacIq* gene, and *btuB* is expressed from *Ptrc*.

To construct plasmid pBtuB2, an SphI/BamHI fragment encoding *lacIq*, *Ptrc*, and *btuB* was removed from pBtuB1 and cloned into the SphI/BamHI sites of plasmid pACYC184. Plasmid pBtuB2 has a p15A origin of replication, chloramphenicol resistance a *lacIq* gene, and *btuB* is expressed from *Ptrc*.

The *btuCED* genes were amplified from *E. coli* chromosomal DNA by PCR using primers (SEQ ID NO:20 with SEQ ID NO:21) which adds a BamHI site at the 5' end and a HindIII site at the 3' end. The 2557 bp PCR product was cloned between the BamHI and HindHIII sites of pACYC184 to generate the plasmid pCED. Plasmid pCED has a P15A origin of replication and a chloramphenicol resistance gene.

To construct plasmid pBCED an Sph/BamHI fragment encoding *lacIq*, *Ptrc* and *btuB* was removed from pBtuB1 and cloned into the SphI/BamHI sites of pCED. Plasmid pBCED has a p15A origin of replication, chloramphenicol resistance, a *lacIq* gene, and the *btu* genes in the order *btuBCED* downstream from a *trc* promoter.

EXAMPLE 2

Transformants Containing Genes For B_{12} Transport And DhaB Activity

E. coli strain FM5 was transformed with the *dha* plasmid pDT24 (specR), the *btuB* plasmids pBtuB1 (ampR) or pBtuB2 (chlR), or the *btuBCED* plasmid

pBCED (chlR). Selection is on LB plates containing 50 mg/L spectinomycin, 50 mg/L ampicillin or 100 mg/L chloramphenicol. Colonies resistant to the appropriate antibiotics were used for 1,3-propanediol production and vitamin or coenzyme B_{12} uptake.

EXAMPLE 3

Increased uptake of coenzyme B_{12} in FM5 transformed with pBCED

The appropriate strains were grown overnight at 37 °C, shaking at 250 rpm, in 250 mL baffled flasks containing 25 mL of broth (broth, titrated to pH 6.8 with NH_4OH, contained 0.2 M KH_2PO_4, 2.0 g/L citric acid, 2.0 g/L $MgSO_4 \cdot 7H_2O$, 1.2 mL 98% H_2SO_4, 0.30 g/L ferric ammonium citrate, 0.20 g/L $CaCl_2 \cdot 2H_2O$, 5 mL of trace metal mix, 5 g/L yeast extract, 10 g/L D-glucose, and appropriate antibiotics. Trace metal mix contained (g/L): Na_2SO_4 (4.0), $MnSO_4 \cdot H_2O$ (0.80), $ZnSO_4 \cdot 7H_2O$ (1.6), $CoSO_4$ (0.52), $CuSO_4 \cdot 5H_2O$ (0.12), and $FeSO_4 \cdot 7H_2O$ (4.0)). Dilutions (1/100) of the overnight cultures were made into 25 mL M9 broth flasks and growth continued until an OD_{660} ~1.0 was reached. When IPTG was added, it was added at this point to 0.2 mM, and incubation was continued for 1 hr.

Cyanocobalamin (cyanocobalamin, CNCbl) or coenzyme B_{12} was added to the M9 cultures at the concentrations. All procedures involving coenzyme B_{12} were performed in the dark (red light). One mL samples were withdrawn immediately upon addition of cobalamin and the cells were pelleted. The cultures were then allowed to incubate further with 250 rpm shaking until endpoint samples were taken as given in Table 1 and Table 2, below.

Cell-free supernatants from each one mL sample were run on HPLC for cobalamin quantification. Cobalamin quantification was achieved by first comparing peak area ratios at 278 nm and 361 nm with standards, and then applying peak areas to standard curves of the cobalamins.

Endpoint analysis involved cell separation from media, followed by separation of periplasm from cytoplasm. Methods followed essentially those of Kaback (Methods of Enzymology, vol. 22, pg. 99, 1971).

Recovered cell pellets were weighed, and washed 2X with 10 mM Tris, pH 8.0. Pellets were resuspended at 1 g/80 mL of 30 mM Tris, pH 8.0/20% sucrose. While stirring on a magnetic stir plate, EDTA was added to 10 mM and lysozyme to 0.5 mg/mL. These suspensions were stirred at room temperature for 30 minutes. Following this lysozyme/EDTA incubation, cells clumped, and sedimented as expected. Each suspension was pelleted at 15K rpm for 20 minutes at 4 °C. Supernatants, now consisting of diluted periplasm, were collected, volumes noted, and samples taken for HPLC analysis.

Recovered spheroplast pellets were homogenized into 3 mLs 50 mM potassium phosphate buffer, pH 7.0 using a tissue homogenizer. Once homogenized, Dnase and Rnase were added to 5 mg/mL, and suspensions incubated in a 37 °C water bath. EDTA was added to 10 mM, and the incubation continued for 15 minutes. $MgSO_4$ was added to 15 mM, and the incubation continued for 15 minutes.

Resulting suspensions were ultracentrifuged at 39K rpm for 1 hour at 4 °C. Supernatants, now consisting of diluted cytoplasm, were collected, volumes noted, and sampled for HPLC analysis.

Periplasm and cytoplasm concentrations of cobalamin were calculated using the assumptions that: 1 ug of cells (wet weight) is equivalent to 1,000,000 cells, the volume of a cell is 9×10^{-13} mL, and the periplasmic volume equals 30% of the total cell volume.

TABLE 1

Effect of pBtuB1A on uptake of 5 uM cyanocobalamin in strain FM5

Strain	Time (hr)	Periplasm	Cytoplasm
FM5	16	6 uM	6.5 uM
FM5/pBtuB1	16	196 uM	45.0 uM

TABLE 2

Effect of pBCED on uptake of 10 uM coenzyme B_{12} in strain FM5

Strain	Time (hr)	Broth	Periplasm	Cytoplasm
FM5/pBtuB2	0	9.7 uM		
+ IPTG	16	Below Detection Limit	840 uM	82 uM
FM5/pBCED	0	10 uM		
+IPTG	16	Below Detection Limit	280 uM	170 uM

EXAMPLE 4

Increased production of 1,3-propanediol from FM5/pDT24 transformed with pBCED

E. coli strains FM5/pDT24 and FM5/pDT24/pBCED were cultured in 250 mL flasks containing 25 mL of medium at 30 °C, protected from light and shaking at 250 rpm. Medium, titrated to pH 6.8 with NH_4OH, contained 0.2 M KH_2PO_4, 2.0 g/L citric acid, 2.0 g/L $MgSO_4 \cdot 7H_20$, 1.2 mL 98% H_2SO_4, 0.30 g/L ferric ammonium citrate, 0.20 g/L $CaCl_2 \cdot 2H_2O$, 5 mL of trace metal mix, 5 g/L yeast extract, 10 g/L D-glucose, and 30 g/L glycerol. Trace metal mix contained (g/L): Na_2SO_4 (4.0), $MnSO_4 \cdot H_20$ (0.80), $ZnSO_4 \cdot 7H_20$ (1.6), $CoSO_4$ (0.52),

$CuSO_4 \cdot 5H_20$ (0.12), and $FeSO_4 \cdot 7H_20$ (4.0). In addition, pDT24 and pBCED required 50 ug/mL spectinomycin and 20 ug/mL chloramphenicol, respectively.

FM5/pDT24 and FM5/pDT24/pBCED were grown as described above with the addition of cyanocobalamin, hydroxocobalamin (hydroxy B_{12}), or coenzyme B_{12} to a final concentration of either 0.40 uM or 4.0 uM. Flasks were inoculated to an initial OD600 of approximately 0.01 AU, pH was maintained above pH 6.2 with the addition of 0.5 N KOH, and the glucose concentration was maintained above 2 g/L with the addition of a 50% (w/w) solution. pH was monitored using ColorpHast strips (EM Science, Gibbstown, NJ). Glucose concentration was monitored using the Trinder enzymatic assay (Sigma, St. Louis, MO). At various times, aliquots were removed in order to determine 3G concentration (hplc analysis) and cell density (OD_{600}). The results are shown in Tables 3 and 4 below.

TABLE 3

Effect of pBCED on the production of 1,3-propanediol in the presence of 0.40 uM vitamin, hydroxy, and coenzyme B_{12}

		FM5/pDT24		FM5/pDT24/pBCED	
B_{12} Addition (0.4 uM)	TIme (hr)	1,3-Propanediol (g/L)	OD600 (AU)	1,3-Propanediol (g/L)	OD600 (AU)
Cyanocobalamin	0	0.0	0.1	0.0	0.0
"	9	0.0	6.3	0.3	6.9
"	11	0.0	9.4	1.0	10.0
"	12	0.0	9.7	1.0	9.9
"	14	0.0	11.6	1.2	12.5
"	17	0.0	19.4	1.2	19.3
"	19	0.0	24.8	1.2	24.1
"	33	0.0	41.5	0.9	46.5
Hydroxy B_{12}	0	0.0	0.1	0.0	0.0
"	9	0.1	6.2	1.0	6.1
"	11	0.3	8.8	2.0	8.3
"	12	0.3	9.7	2.2	9.1
"	14	0.3	10.4	2.3	10.5
"	17	0.4	17.3	2.3	15.8
"	19	0.4	22.0	2.2	18.2
	33	0.2	41.5	1.5	35.8

		FM5/pDT24		FM5/pDT24/pBCED	
B_{12} Addition (0.4 uM)	TIme (hr)	1,3-Propanediol (g/L)	OD600 (AU)	1,3-Propanediol (g/L)	OD600 (AU)
Coenzyme B_{12}	0	0.0	0.0	0.0	0.0
"	9	1.7	6.9	1.3	6.2
"	11	2.0	10.1	2.4	9.2
"	12	2.1	10.1	3.1	9.7
"	14	3.0	12.2	3.3	10.9
"	17	2.5	17.4	2.8	17.4
"	19	2.3	22.2	3.2	21.1
"	33	1.8	46.7	2.4	48.7

TABLE 4

Effect of pBCED on the production of 1,3-propanediol in the presence of 4.0 uM vitamin, hydroxy, and coenzyme B_{12}

		FM5/pDT24		FM5/pDT24/pBCED	
B_{12} Addition (4.0 uM)	TIme (hr)	1,3-Propanediol (g/L)	OD600 (AU)	1,3-Propanediol (g/L)	OD600 (AU)
Cyanocobalamin	0	0.0	0.2	0.0	0.1
"	8	0.1	8.9	0.4	9.7
"	10	0.1	11.9	0.8	11.6
"	12	0.3	13.7	1.5	15.9
"	14	0.8	17.8	3.3	23.0
"	16	1.3	24.7	6.1	29.6
"	33	1.6	36.6	10.2	40.7
Hydroxy B_{12}	0	0.0	0.1	0.0	0.1
"	8	0.4	9.0	1.7	9.5
"	10	1.3	11.5	2.7	12.2
"	12	2.8	12.9	3.8	14.6
"	14	4.2	16.1	5.4	18.9
"	16	5.5	19.9	7.2	25.1
"	33	7.3	49.1	13.1	43.8

		FM5/pDT24		FM5/pDT24/pBCED	
B_{12} Addition (4.0 uM)	TIme (hr)	1,3-Propanediol (g/L)	OD600 (AU)	1,3-Propanediol (g/L)	OD600 (AU)
Coenzyme B_{12}	0	0.0	0.1	0.0	0.2
"	8	2.4	8.2	2.2	8.7
"	10	3.7	10.3	3.3	11.5
"	12	5.0	12.6	4.2	13.2
"	14	5.5	14.2	5.7	16.5
"	16	7.4	16.6	7.3	20.4
"	33	11.3	46.2	12.7	48.6

WE CLAIM:

1. A process for the bio-production of 1,3-propanediol comprising:

(i) contacting a transformed host cell with at least one fermentable carbon source and an effective amount of vitamin B_{12} whereby 1,3-propanediol is produced, the transformed host cell comprising:

(a) at least one copy of a gene encoding a protein having a dehydratase activity;

(b) at least one copy of a gene encoding a protein having an oxidoreductase activity;

(c) at least one copy of a gene encoding a vitamin B_{12} receptor precursor protein;

(d) at least one copy of a gene encoding a vitamin B_{12} transport system permease protein; and

(e) at least one copy of a gene encoding vitamin B_{12} transport ATP- or GTP-binding protein;

wherein at least one copy of any of the genes of (c), (d) or (e) is introduced into the host cell, and

(ii) recovering the 1,3-propanediol produced from step (i).

2. The process of Claim 1 wherein the gene encoding a protein having a dehydratase activity of step 1(a) encodes an enzyme selected from the group consisting of a glycerol dehydratase enzyme and a diol dehydratase enzyme.

3. The process of Claim 1 wherein the genes of 1(a) and 1(b) are independently isolated from *Klebsiella sp.*, *Citrobacter sp.*, *Salmonella sp.*, or *Clostridium sp.*

4. The process of Claim 1 wherein the genes of 1(c), 1(d), and 1(e) are independently isolated from *Escherichia sp.*, *Salmonella sp.*, *Klebsiella sp.*, *Pseudomonas sp.*, or *Citrobacter sp.*

5. The process of Claim 1 wherein:

(i) the gene of (i)(c) is a *btuB* gene selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2;

(ii) the gene of (i)(d) is a *btuC* gene of SEQ ID NO:3; and

(iii) the gene of (i)(e) is a *btuD* gene of SEQ ID NO:4.

6. The process of Claim 1 wherein the fermentable carbon source is selected from the group consisting of fermentable carbohydrates, single-carbon substrates, and mixtures thereof.

7. The process of Claim 1 wherein the fermentable carbon source is selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, single carbon substrates, glycerol, dihydroxyacetone and carbon-containing amines.

8. The process of Claim 1 wherein the transformed host cell further comprises at least one copy of a gene encoding a glycerol-3-phosphate dehydrogenase enzyme and at least one copy of a gene encoding a glycerol-3-phosphatase enzyme.

9. The process of Claim 1 wherein the host cell is selected from the group consisting of bacteria, yeast, and filamentous fungi.

10. The process of Claim 9 wherein the host cell is selected from the group of genera consisting of *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces*, and *Pseudomonas*.

11. The process of Claim 1 wherein the effective amount of vitamin B_{12} is at a 0.1- to 10.0-fold molar ratio to the amount of dehydratase present.

12. A transformed host cell comprising:

(a) at least one copy of a gene encoding a protein having a dehydratase activity;

(b) at least one copy of a gene encoding a protein having an oxidoreductase activity;

(c) at least one copy of a gene encoding a vitamin B_{12} receptor precursor protein;

(d) at least one copy of a gene encoding a vitamin B_{12} transport system permease protein; and

(e) at least one copy of a gene encoding vitamin B_{12} transport ATP- or GTP-binding protein;

wherein at least one copy of the gene of (i)(c), (i)(d), or (i)(e) is introduced into the host cell.

13. A process for the bio-production of 1,3-propanediol comprising:

(i) contacting a transformed host cell with (a) at least one fermentable carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, single carbon substrates, glycerol, dihydroxyacetone and carbon-containing amines and (b) an effective amount of vitamin B_{12}, whereby 1,3-propanediol is produced, the transformed host cell comprising:

(a) at least one copy of a gene encoding a protein having a dehydratase activity;

(b) at least one copy of a gene encoding a protein having an oxidoreductase activity;

(c) at least one copy of a gene encoding a vitamin B_{12} receptor precursor protein;

(d) at least one copy of a gene encoding a vitamin B_{12} transport system permease protein; and

(e) at least one copy of a gene encoding vitamin B_{12} transport ATP- or GTP-binding protein;

(f) at least one copy of a gene encoding a protein having a glycerol-3-phosphate dehydrogenase activity; and

(g) at least one copy of a gene encoding a protein having a glycerol-3-phosphatase activity,

wherein at least one copy of any of the genes of (i)(c), (i)(d) or (i)(e) is introduced into the host cell, and

(ii) recovering the 1,3-propanediol produced from step (i).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:
(A) ADDRESSEE: E. I. DUPONT DE NEMOURS AND COMPANY
(B) STREET: 1007 MARKET STREET
(C) CITY: WILMINGTON
(D) STATE: DELAWARE
(E) COUNTRY: U.S.A.
(F) ZIP: 19898
(G) TELEPHONE: 302-892-8112
(H) TELEFAX: 302-773-0164
(I) TELEX: 6717325

(A) ADDRESSEE: GENENCOR INTERNATIONAL, INC.
(B) STREET: 925 PAGE MILL ROAD
(C) CITY: PALO ALTO
(D) STATE: CALIFORNIA
(E) COUNTRY: U.S.A.
(F) ZIP: 94304-1013

(ii) TITLE OF INVENTION: METHOD FOR THE PRODUCTION OF 1,3-PROPANEDIOL BY RECOMBINANT ORGANISMS COMPRISING GENES FOR VITAMIN B_{12} TRANSPORT

(iii) NUMBER OF SEQUENCES: 25

(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: DISKETTE, 3.50 INCH
(B) COMPUTER: IBM PC COMPATIBLE
(C) OPERATING SYSTEM: MICROSOFT WINDOWS 95
(D) SOFTWARE: MICROSOFT OFFICE 97

(v) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 60/085,190
(B) FILING DATE: JUNE 30, 1998
(C) CLASSIFICATION:

(vii) ATTORNEY/AGENT INFORMATION:
(A) NAME: FLOYD, LINDA AXAMETHY
(B) REGISTRATION NO.: 33,692
(C) REFERENCE/DOCKET NUMBER: CL-1245-A

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1845 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGATTAAAA AGCTTCCCT GCTGACGGCG TGTTCCGTCA CGGCATTTTC CGCTTGGGCA 60

CAGGATACCA GCCCGGATAC TCTCGTCGTT ACTGCTAACC GTTTTGAACA GCCGCGCAGC 120

ACTGTGCTTG CACCAACCAC CGTTGTGACC CGTCAGGATA TCGACCGCTG GCAGTCGACC 180

TCGGTCAATG ATGTGCTGCG CCGTCTTCCG GGCGTCGATA TCACCCAAAA CGGCGGTTCA 240

GGTCAGCTCT CATCTATTTT TATTCGCGGT ACAAATGCCA GTCATGTGTT GGTGTTAATT 300

GATGGCGTAC GCCTGAATCT GGCGGGGGTG AGTGGTTCTG CCGACCTTAG CCAGTTCCCT 360

ATTGCGCTTG TCCAGCGTGT TGAATATATC CGTGGGCCGC GCTCCGCTGT TTATGGTTCC 420

GATGCAATAG GCGGGGTGGT GAATATCATC ACGACGCGCG ATGAACCCGG AACGGAAATT 480

TCAGGAGGGT GGGGAAGCAA TAGTTATCAG AACTATGATG TCTCTACGCA GCAACAACTG 540

GGGGATAAGA CACGGGTAAC GCTGTTGGGC GATTATGCCC ATACTCATGG TTATGATGTT 600

GTTGCCTATG GTAATACCGG AACGCAAGCG CAGACAGATA ACGATGGTTT TTTAAGTAAA 660

ACGCTTTATG GCGCGCTGGA GCATAACTTT ACTGATGCCT GGAGCGGCTT TGTGCGCGGC 720

TATGGCTATG ATAACCGTAC CAATTATGAC GCGTATTATT CTCCCGGTTC ACCGTTGCTC 780

GATACCCGTA AACTCTATAG CCAAAGTTGG GACGCCGGGC TGCGCTATAA CGGCGAACTG 840

ATTAAATCAC AACTCATTAC CAGCTATAGC CATAGCAAAG ATTACAACTA CGATCCCCAT 900

TATGGTCGTT ATGATTCGTC GGCGACGCTC GATGAGATGA AGCAATACAC CGTCCAGTGG 960

GCAAACAATG TCATCGTTGG TCACGGTAGT ATTGGTGCGG GTGTCGACTG GCAGAAACAG 1020

ACTACGACGC CGGGTACAGG TTATGTTGAG GATGGATATG ATCAACGTAA TACCGGCATC 1080

TATCTGACCG GGCTGCAACA AGTCGGCGAT TTTACCTTTG AAGGCGCCAG ACGCAGTGAC 1140

GATAACTCAC AGTTTGGTCG TCATGGAACC TGGCAAACCA GCGCCGGTTG GGAATTCATC 1200

GAAGGTTATC GCTTCATTGC TTCCTACGGG ACATCTTATA AGGCACCAAA TCTGGGGCAA 1260

CTGTATGGCT TCTACGGAAA TCCGAATCTG GACCCGGAGA AAAGCAAACA GTGGGAAGGC 1320

GCGTTTGAAG GCTTAACCGC TGGGGTGAAC TGGCGTATTT CCGGATATCG TAACGATGTC 1380

AGTGACTTGA TCGATTATGA TGATCACACC CTGAAATATT ACAACGAAGG GAAAGCGCGG 1440

ATTAAGGGCG TCGAGGCGAC CGCCAATTTT GATACCGGAC CACTGACGCA TACTGTGAGT 1500

TATGATTATG TCGATGCGCG CAATGCGATT ACCGACACGC CGTTGTTACG CCGTGCTAAA 1560

CAGCAGGTGA AATACCAGCT CGACTGGCAG TTGTATGACT TCGACTGGGG TATTACTTAT 1620

CAGTATTTAG GCACTCGCTA TGATAAGGAT TACTCATCTT ATCCTTATCA AACCGTTAAA 1680

ATGGGCGGTG TGAGCTTGTG GGATCTTGCG GTTGCGTATC CGGTCACCTC TCACCTGACA 1740

GTTCGTGGTA AAATAGCCAA CCTGTTCGAC AAAGATTATG AGACAGTCTA TGGCTACCAA 1800

ACTGCAGGAC GGGAATACAC CTTGTCTGGC AGCTACACCT TCTGA 1845

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1844 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGATTAAAA AGCTACGCT GCTGACGGCG TTCTCCGTCA CGGCCTTTTC CGCTTGGGCG 60

CAGGACACTA GCCCGGATAC CCTGGTTGTC ACCGCCAACC GTTTTCAGCA GCCGCGCAGC 120

GCGGTTCTGG CGCCCGTTAC CATCGTGACG CGTCAGGATA TTGAACGCTG GCAATCGACC 180

TCCGTAAATG ATGTTCTGCG CCGTTTGCCT GGCGTCGATA TTGCGCAGAG CGGCGGCGCG 240

CGACAAAACT CCTCCATTTT CATTCGCGGC ACCAACTCCA GCCATGTACT GGTATTGATT 300

GACGGCGTGC GTCTGAATTT AGCAGGCGTG AGCGGGTCCG CCGATCTCAG CCAGTTCCCG 360

GTGTCGCTGG TACAGCGTAT TGAATATATA CGCGGTCCGC CCTCCGCTAT TTATGGTTCC 420

GATGCTATCG GCGGCGTAGT GAATATCATT ACGACGCGCG ATAACCCAGG CACAGAATTA 480

ACCGCTGGAT GGGGAAGCAA TAGCTACCAG AATTACGACA TCTCGACGCA ACAGCAACTT 540

GGCGAAATCA CGCGGGCGAC GTTGATCGGC GATTACGAAT ACACCAAAGG GTTTGACGTG 600

GTAGCGAAAG GCGGTACCGG GATGCAGGCG CAGCCTGACC GGGACGGCTT TTTGAGTAAA 660

ACGCTTTATG GCGCGTTAGA GCATACCTTT TCTGATCGCT GGAGCGGATT CGTGCGTGGT 720

TATGGCTACG ATAACCGTAC CGATTACGAC GCCTATTACT CGCCGGGCTC GCCGCTGATT 780

GATACACGCA AACTTTATAG CCAAAGCTGG GACGCCGGGC TGCACTTTAA TGGCGAAAGT 840

ATTCAGTCTC AGCTGGTTTC AAGCTATAGC CACAGTAAAG ATTACAACTA TGATCCGCAC 900

TATGGCCGGT ATGATACCTC CGCCACGCTG GATGAGATGA AACAGTACAA TGTTCAATGG 960

ACCAACAGTG TGGTCGTGGG GACGGTAATG TTGGGGCGGG CGTAGACTGG CAGAAACAGA 1020

CTACCACGCC AGGTACCGGC TATGTGCCCG AGGGATATGA CCAGCGTAAT ACCGGGGTTT 1080

ACCTGACAGG ATTACAACAG TTGGGTGACT TCACTCTGGA AGCGGCGGCG CGCAGTGATG 1140

ACAACTCCCA GTTTGGTCGT CATGGTACAT GGCAAACCAG CGCGGGATGG GAGTTTATAG 1200

AAGGTTATCG CTTTATTGCC TCCTACGGAA CCTCCTACAA AGCGCCTAAT TTGGGCCAAC 1260

TGTATGGTTA TTACGGTAAT CCGAACCTGA ATCCTGAAAA GAGTAAACAG TGGGAAGGCG 1320

CATTTGAAGG GCTAACCGCT GGCGTCAGCT GGCGTATTTC AGGTTATCGT AACGATATTA 1380

ATGACATGAT CGATTATGAC GATCATCTGC AAAAATATTA CAACGAAGGT AAGGCGCGCA 1440

TTAAAGGTAT TGAGGCGACG GCGAATTTCG ATACCGGACC GTTAACGCAT ACGGTCAGTT 1500

ATGATTACGT TGATGCGCGT AATGCGATTA CCGATACGCC ATTACCCCGG CGTTCCAAAC 1560

AGATGGCAAA ATATCAACTT GACTGGGACG TTTACGATTT TGACTGGGGG ATGACATATC 1620

AATACCTTGG TTCCCGCTAT GATTCGGATT ACTCCGCTTA CCCATACCGG ACAGTAAAAA 1680

TGGGCGGCGT CAGTTTATGG GATCTTACGG TTGCATATCC GGTCACCTCA CATCTGACAG 1740

TTCGTGGTAA AATAGCCAAC CTGTTCGACA AAGATTACGA GACAGTTTAT GGCTACCAAA 1800

CTGCAGGACG AGAATACACC TTGTCTGGCA GCTACACCTT CTGA 1844

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 981 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGCTGACAC TTGCCCGCCA ACAACAGCGA CAAAATATTC GCTGGTTATT ATGCCTGTCA 60

GTTTTGATGC TGCTGGCGCT TCTCTTAAGC CTTTGCGCCG GTGAACAATG GATCTCGCCA 120

GGTGACTGGT TTACTCCTCG TGGCGAACTG TTCGTCTGGC AAATTCGCCT GCCACGTACG 180

CTGGCTGTAT TGCTGGTTGG TGCGGCGCTG GCTATATCCG GCGCTGTAAT GCAGGCGTTG 240

TTTGAAAATC CTCTGGCAGA ACCTGGACTA CTTGGCGTCT CTAACGGCGC AGGCGTGGGG 300

CTTATCGCCG CGGTATTGCT TGGGCAAGGG CTAACTCCCA ACTGGGCGCT AGGGCTGTGT 360

GCGATTCGTG GCGCGCTTAT CATCACTTTA ATACTCTTAC GTTTCGCCCG TCGTCATCTT 420

TCGACCAGTC GGTTATTGCT GGCTGGCGTT GCATTAGGGA TTATCTGTAG CGCACTAATG 480

ACGTGGGCTA TCTACTTTTC CACCTCAGTT GATTTGCGTC AGCTGATGTA CTGGATGATG 540

GGCGGTTTTG GCGGCGTAGA CTGGCGGCAA AGCTGGCTGA TGCTGGCATT GATCCCCGTG 600

TTGTTGTGGA TCTGTTGTCA GTCCAGGCCG ATGAATATGT TAGCACTTGG CGAGATCTCG 660

GCGCGGCAAC TGGGTTTACC CCTGTGGTTC TGGCGCAATG TGCTGGTGGC AGCGACCGGC 720

TGGATGGTTG GCGTCAGTGT GGCGCTGGCG GGTGCTATCG GCTTTATTGG TCTGGTGATC 780

CCCCATATTC TCCGGTTGTG TGGTTTAACC GATCATCGCG TATTACTTCC CGGCTGCGCG 840

CTGGCAGGGG CGAGCGCATT GCTGCTGGCC GATATTGTAG CGCGCCTGGC ATTAGCTGCC 900

GCAGAGCTGC CTATTGGCGT GGTCACCGCA ACGTTAGGTG CGCCGGTGTT TATCTGGTTA 960

TTGTTAAAAG CAGGACGTTA G 981

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 750 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ATGTCTATTG TGATGCAGTT ACAAGATGTT GCGGAATCTA CCCGCCTGGG GCCGCTTTCT 60

GGCGAGGTTC GGGCTGGGGA GATCCTGCAC CTGGTGGGGC CGAATGGCGC GGGTAAGAGT 120

ACCTTACTGG CGCGAATGGC CGGAATGACC AGCGGTAAGG GAAGCATTCA GTTCGCGGGG 180

CAACCACTGG AAGCATGGTC CGCAACAAAA CTCGCGCTGC ATCGCGCCTA TCTTTCACAA 240

CAGCAGACGC CGCCGTTTGC AACGCCGGTC TGGCACTACC TGACACTGCA TCAGCACGAT 300

AAAACGCGTA CCGAACTACT GAATGATGTC GCAGGGGCGC TGGCTCTTGA TGACAAACTC 360

GGACGTAGCA CCAATCAACT TTCCGGCGGT GAATGGCAAC GCGTACGTCT TGCTGCGGTG 420

GTGTTGCAAA TCACACCACA AGCCAATCCC GCAGGCCAAT TGCTGCTTCT TGATGAGCCG 480

ATGAACAGTC TTGATGTTGC GCAACAAAGT GCGTTAGACA AAATTCTGAG CGCGCTGTGT 540

CAGCAAGGAC TGGCGATTGT GATGAGCAGT CACGATCTCA ACCACACATT GCGTCATGCG 600

CATCGGGCGT GGTTGCTAAA AGGTGGAAAA ATGCTGGCCA GTGGACGCAG GGAAGAGGTG 660

CTCACGCCGC CAAATCTGGC GCAGGCCTAT GGGATGAATT TTCGCCGTCT GGATATCGAA 720

GGTCACAGAA TGCTGATTTC GACCATCTGA 750

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 552 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATGCAAGATT CCATTCTGAC GACCGTAGTG AAAGATATCG ACGGTGAAGT GACCACGCTG 60

GAGAAGTTCG CCGGTAATGT GCTGTTGATT GTCAATGTCG CCTCAAAGTG TGGCTTAACG 120

CCGCAATATG AGCAGTTGGA GAATATTCAG AAAGCCTGGG TCGATCGAGG TTTTATGGTG 180

CTGGGATTCC CGTGCAACCA GTTTCTGGAA CAAGAACCGG GCAGCGATGA AGAGATTAAA 240

ACTTACTGTA CCACCACATG GGGGGTGACG TTCCCGATGT TCAGTAAGAT TGAAGTTAAT 300

GGCGAAGGAC GCCATCCGCT GTATCAAAAA TTGATTGCCG CAGCGCCGAC CGCAGTCGCG 360

CCGGAAGAGA GCGGATTCTA TGCCCGTATG GTCAGCAAAG GCCGTGCACC GCTGTACCCG 420

GATGATATTT TATGGAATTT TGAAAAATTC CTGGTTGGCA GGGACGGAAA AGTCATCCAG 480

CGTTTTTCCC CGGATATGAC GCCGGAAGAT CCCATTGTGA TGGAAAGCAT TAAACTGGCG 540

TTGGCAAAAT AA 552

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1668 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

ATGAAAAGAT CAAAACGATT TGCAGTACTG GCCCAGCGCC CCGTCAATCA GGACGGGCTG 60

ATTGGCGAGT GGCCTGAAGA GGGGCTGATC GCCATGGACA GCCCCTTTGA CCCGGTCTCT 120

TCAGTAAAAG TGGACAACGG TCTGATCGTC GAACTGGACG GCAAACGCCG GGACCAGTTT 180

GACATGATCG ACCGATTTAT CGCCGATTAC GCGATCAACG TTGAGCGCAC AGAGCAGGCA 240

ATGCGCCTGG AGGCGGTGGA AATAGCCCGT ATGCTGGTGG ATATTCACGT CAGCCGGGAG 300

GAGATCATTG CCATCACTAC CGCCATCACG CCGGCCAAAG CGGTCGAGGT GATGGCGCAG 360

ATGAACGTGG TGGAGATGAT GATGGCGCTG CAGAAGATGC GTGCCCGCCG GACCCCCTCC 420

AACCAGTGCC ACGTCACCAA TCTCAAAGAT AATCCGGTGC AGATTGCCGC TGACGCCGCC 480

GAGGCCGGGA TCCGCGGCTT CTCAGAACAG GAGACCACGG TCGGTATCGC GCGCTACGCG 540

CCGTTTAACG CCCTGGCGCT GTTGGTCGGT TCGCAGTGCG GCCGCCCCGG CGTGTTGACG 600

CAGTGCTCGG TGGAAGAGGC CACCGAGCTG GAGCTGGGCA TGCGTGGCTT AACCAGCTAC 660

GCCGAGACGG TGTCGGTCTA CGGCACCGAA GCGGTATTTA CCGACGGCGA TGATACGCCG 720

TGGTCAAAGG CGTTCCTCGC CTCGGCCTAC GCCTCCCGCG GGTTGAAAAT GCGCTACACC 780

TCCGGCACCG GATCCGAAGC GCTGATGGGC TATTCGGAGA GCAAGTCGAT GCTCTACCTC 840

GAATCGCGCT GCATCTTCAT TACTAAAGGC GCCGGGGTTC AGGGACTGCA AAACGGCGCG 900

GTGAGCTGTA TCGGCATGAC CGGCGCTGTG CCGTCGGGCA TTCGGGCGGT GCTGGCGGAA 960

AACCTGATCG CCTCTATGCT CGACCTCGAA GTGGCGTCCG CCAACGACCA GACTTTCTCC 1020

CACTCGGATA TTCGCCGCAC CGCGCGCACC CTGATGCAGA TGCTGCCGGG CACCGACTTT 1080

ATTTTCTCCG GCTACAGCGC GGTGCCGAAC TACGACAACA TGTTCGCCGG CTCGAACTTC 1140

GATGCGGAAG ATTTTGATGA TTACAACATC CTGCAGCGTG ACCTGATGGT TGACGGCGGC 1200

CTGCGTCCGG TGACCGAGGC GGAAACCATT GCCATTCGCC AGAAAGCGGC GCGGGCGATC 1260

CAGGCGGTTT TCCGCGAGCT GGGGCTGCCG CCAATCGCCG ACGAGGAGGT GGAGGCCGCC 1320

ACCTACGCGC ACGGCAGCAA CGAGATGCCG CCGCGTAACG TGGTGGAGGA TCTGAGTGCG 1380

GTGGAAGAGA TGATGAAGCG CAACATCACC GGCCTCGATA TTGTCGGCGC GCTGAGCCGC 1440

AGCGGCTTTG AGGATATCGC CAGCAATATT CTCAATATGC TGCGCCAGCG GGTCACCGGC 1500

GATTACCTGC AGACCTCGGC CATTCTCGAT CGGCAGTTCG AGGTGGTGAG TGCGGTCAAC 1560

GACATCAATG ACTATCAGGG GCCGGGCACC GGCTATCGCA TCTCTGCCGA ACGCTGGGCG 1620

GAGATCAAAA ATATTCCGGG CGTGGTTCAG CCCGACACCA TTGAATAA 1668

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 585 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GTGCAACAGA CAACCCAAAT TCAGCCCTCT TTTACCCTGA AAACCCGCGA GGGCGGGGTA 60

GCTTCTGCCG ATGAACGCGC CGATGAAGTG GTGATCGGCG TCGGCCCTGC CTTCGATAAA 120

CACCAGCATC ACACTCTGAT CGATATGCCC CATGGCGCGA TCCTCAAAGA GCTGATTGCC 180

GGGGTGGAAG AAGAGGGGCT TCACGCCCGG GTGGTGCGCA TTCTGCGCAC GTCCGACGTC 240

TCCTTTATGG CCTGGGATGC GGCCAACCTG AGCGGCTCGG GGATCGGCAT CGGTATCCAG 300

TCGAAGGGGA CCACGGTCAT CCATCAGCGC GATCTGCTGC CGCTCAGCAA CCTGGAGCTG 360

TTCTCCCAGG CGCCGCTGCT GACGCTGGAG ACCTACCGGC AGATTGGCAA AAACGCTGCG 420

CGCTATGCGC GCAAAGAGTC ACCTTCGCCG GTGCCGGTGG TGAACGATCA GATGGTGCGG 480

CCGAAATTTA TGGCCAAAGC CGCGCTATTT CATATCAAAG AGACCAAACA TGTGGTGCAG 540

GACGCCGAGC CCGTCACCCT GCACATCGAC TTAGTAAGGG AGTGA 585

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 426 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ATGAGCGAGA AAACCATGCG CGTGCAGGAT TATCCGTTAG CCACCCGCTG CCCGGAGCAT 60

ATCCTGACGC CTACCGGCAA ACCATTGACC GATATTACCC TCGAGAAGGT GCTCTCTGGC 120

GAGGTGGGCC CGCAGGATGT GCGGATCTCC CGCCAGACCC TTGAGTACCA GGCGCAGATT 180

GCCGAGCAGA TGCAGCGCCA TGCGGTGGCG CGCAATTTCC GCCGCGCGGC GGAGCTTATC 240

GCCATTCCTG ACGAGCGCAT TCTGGCTATC TATAACGCGC TGCGCCCGTT CCGCTCCTCG 300

CAGGCGGAGC TGCTGGCGAT CGCCGACGAG CTGGAGCACA CCTGGCATGC GACAGTGAAT 360

GCCGCCTTTG TCCGGGAGTC GGCGGAAGTG TATCAGCAGC GGCATAAGCT GCGTAAAGGA 420

AGCTAA 426

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1164 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATGAGCTATC GTATGTTTGA TTATCTGGTG CCAAACGTTA ACTTTTTTGG CCCCAACGCC 60

ATTTCCGTAG TCGGCGAACG CTGCCAGCTG CTGGGGGGGA AAAAAGCCCT GCTGGTCACC 120

GACAAAGGCC TGCGGGCAAT TAAAGATGGC GCGGTGGACA AAACCCTGCA TTATCTGCGG 180

GAGGCCGGGA TCGAGGTGGC GATCTTTGAC GGCGTCGAGC CGAACCCGAA AGACACCAAC 240

GTGCGCGACG GCCTCGCCGT GTTTCGCCGC GAACAGTGCG ACATCATCGT CACCGTGGGC 300

GGCGGCAGCC CGCACGATTG CGGCAAAGGC ATCGGCATCG CCGCCACCCA TGAGGGCGAT 360

CTGTACCAGT ATGCCGGAAT CGAGACCCTG ACCAACCCGC TGCCGCCTAT CGTCGCGGTC 420

AATACCACCG CCGGCACCGC CAGCGAGGTC ACCCGCCACT GCGTCCTGAC CAACACCGAA 480

ACCAAAGTGA AGTTTGTGAT CGTCAGCTGG CGCAAACTGC CGTCGGTCTC TATCAACGAT 540

CCACTGCTGA TGATCGGTAA ACCGGCCGCC CTGACCGCGG CGACCGGGAT GGATGCCCTG 600

ACCCACGCCG TAGAGGCCTA TATCTCCAAA GACGCTAACC CGGTGACGGA CGCCGCCGCC 660

ATGCAGGCGA TCCGCCTCAT CGCCCGCAAC CTGCGCCAGG CCGTGGCCCT CGGCAGCAAT 720

CTGCAGGCGC GGGAAAACAT GGCCTATGCT TCTCTGCTGG CCGGGATGGC TTTCAATAAC 780

GCCAACCTCG GCTACGTGCA CGCCATGGCG CACCAGCTGG GCGGCCTGTA CGACATGCCG 840

CACGGCGTGG CCAACGCTGT CCTGCTGCCG CATGTGGCGC GCTACAACCT GATCGCCAAC 900

CCGGAGAAAT TCGCCGATAT CGCTGAACTG ATGGGCGAAA ATATCACCGG ACTGTCCACT 960

CTCGACGCGG CGGAAAAAGC CATCGCCGCT ATCACGCGTC TGTCGATGGA TATCGGTATT 1020

CCGCAGCATC TGCGCGATCT GGGGGTAAAA GAGGCCGACT TCCCCTACAT GGCGGAGATG 1080

GCTCTAAAAG ACGGCAATGC GTTCTCGAAC CCGCGTAAAG GCAACGAGCA GGAGATTGCC 1140

GCGATTTTCC GCCAGGCATT CTGA 1164

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12145 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GTCGACCACC ACGGTGGTGA CTTTAATGCC GCTCTCATGC AGCAGCTCGG TGGCGGTCTC 60

AAAATTCAGG ATGTCGCCGG TATAGTTTTT GATAATCAGC AAGACGCCTT CGCCGCCGTC 120

AATTTGCATC GCGCATTCAA ACATTTTGTC CGGCGTCGGC GAGGTGAATA TTTCCCCCGG 180

ACAGGCGCCG GAGAGCATGC CCTGGCCGAT ATAGCCGCAG TGCATCGGTT CATGTCCGCT 240

GCCGCCGCCG GAGAGCAGGG CCACCTTGCC AGCCACCGGC GCGTCGGTGC GGGTCACATA 300

CAGCGGGTCC TGATGCAGGG TCAGCTGCGG ATGGGCTTTA GCCAGCCCCT GTAATTGTTC 360

ATTCAGTACA TCTTCAACAC GGTTAATCAG CTTTTTCATT ATTCAGTGCT CCGTTGGAGA 420

AGGTTCGATG CCGCCTCTCT GCTGGCGGAG GCGGTCATCG CGTAGGGGTA TCGTCTGACG 480

GTGGAGCGTG CCTGGCGATA TGATGATTCT GGCTGAGCGG ACGAAAAAAA GAATGCCCCG 540

ACGATCGGGT TTCATTACGA AACATTGCTT CCTGATTTTG TTTCTTTATG GAACGTTTTT 600

GCTGAGGATA TGGTGAAAAT GCGAGCTGGC GCGCTTTTTT TCTTCTGCCA TAAGCGGCGG 660

TCAGGATAGC CGGCGAAGCG GGTGGGAAAA AATTTTTTGC TGATTTTCTG CCGACTGCGG 720

GAGAAAAGGC GGTCAAACAC GGAGGATTGT AAGGGCATTA TGCGGCAAAG GAGCGGATCG 780

GGATCGCAAT CCTGACAGAG ACTAGGGTTT TTTGTTCCAA TATGGAACGT AAAAAATTAA 840

CCTGTGTTTC ATATCAGAAC AAAAAGGCGA AAGATTTTTT TGTTCCCTGC CGGCCCTACA 900

GTGATCGCAC TGCTCCGGTA CGCTCCGTTC AGGCCGCGCT TCACTGGCCG GCGCGGATAA 960

CGCCAGGGCT CATCATGTCT ACATGCGCAC TTATTTGAGG GTGAAAGGAA TGCTAAAAGT 1020

TATTCAATCT CCAGCCAAAT ATCTTCAGGG TCCTGATGCT GCTGTTCTGT TCGGTCAATA 1080

TGCCAAAAAC CTGGCGGAGA GCTTCTTCGT CATCGCTGAC GATTTCGTAA TGAAGCTGGC 1140

GGGAGAGAAA GTGGTGAATG GCCTGCAGAG CCACGATATT CGCTGCCATG CGGAACGGTT 1200

TAACGGCGAA TGCAGCCATG CGGAAATCAA CCGTCTGATG GCGATTTTGC AAAAACAGGG 1260

CTGCCGCGGC GTGGTCGGGA TCGGCGGTGG TAAAACCCTC GATACCGCGA AGGCGATCGG 1320

TTACTACCAG AAGCTGCCGG TGGTGGTGAT CCCGACCATC GCCTCGACCG ATGCGCCAAC 1380

CAGCGCGCTG TCGGTGATCT ACACCGAAGC GGGCGAGTTT GAAGAGTATC TGATCTATCC 1440

GAAAAACCCG GATATGGTGG TGATGGACAC GGCGATTATC GCCAAAGCGC CGGTACGCCT 1500

GCTGGTCTCC GGCATGGGCG ATGCGCTCTC CACCTGGTTC GAGGCCAAAG CTTGCTACGA 1560

TGCGCGCGCC ACCAGCATGG CCGGAGGACA GTCCACCGAG GCGGCGCTGA GCCTCGCCCG 1620

CCTGTGCTAT GATACGCTGC TGGCGGAGGG CGAAAAGGCC CGTCTGGCGG CGCAGGCCGG 1680

GGTAGTGACC GAAGCGCTGG AGCGCATCAT CGAGGCGAAC ACTTACCTCA GCGGCATTGG 1740

CTTTGAAAGC AGTGGCCTGG CCGCTGCCCA TGCAATCCAC AACGGTTTCA CCATTCTTGA 1800

AGAGTGCCAT CACCTGTATC ACGGTGAGAA AGTGGCCTTC GGTACCCTGG CGCAGCTGGT 1860

GCTGCAGAAC AGCCCGATGG ACGAGATTGA AACGGTGCAG GGCTTCTGCC AGCGCGTCGG 1920

CCTGCCGGTG ACGCTCGCGC AGATGGGCGT CAAAGAGGGG ATCGACGAGA AAATCGCCGC 1980

GGTGGCGAAA GCTACCTGCG CGGAAGGGGA AACCATCCAT AATATGCCGT TTGCGGTGAC 2040

CCCGGAGAGC GTCCATGCCG CTATCCTCAC CGCCGATCTG TTAGGCCAGC AGTGGCTGGC 2100

GCGTTAATTC GCGGTGGCTA AACCGCTGGC CCAGGTCAGC GGTTTTTCTT TCTCCCCTCC 2160

GGCAGTCGCT GCCGGAGGGG TTCTCTATGG TACAACGCGG AAAAGGATAT GACTGTTCAG 2220

ACTCAGGATA CCGGGAAGGC GGTCTCTTCC GTCATTGCCC AGTCATGGCA CCGCTGCAGC 2280

AAGTTTATGC AGCGCGAAAC CTGGCAAACG CCGCACCAGG CCCAGGGCCT GACCTTCGAC 2340

TCCATCTGTC GGCGTAAAAC CGCGCTGCTC ACCATCGGCC AGGCGGCGCT GGAAGACGCC 2400

TGGGAGTTTA TGGACGGCCG CCCCTGCGCG CTGTTTATTC TTGATGAGTC CGCCTGCATC 2460

CTGAGCCGTT GCGGCGAGCC GCAAACCCTG GCCCAGCTGG CTGCCCTGGG ATTTCGCGAC 2520

GGCAGCTATT GTGCGGAGAG CATTATCGGC ACCTGCGCGC TGTCGCTGGC CGCGATGCAG 2580

GGCCAGCCGA TCAACACCGC CGGCGATCGG CATTTTAAGC AGGCGCTACA GCCATGGAGT 2640

TTTTGCTCGA CGCCGGTGTT TGATAACCAC GGGCGGCTGT TCGGCTCTAT CTCGCTTTGC 2700

TGTCTGGTCG AGCACCAGTC CAGCGCCGAC CTCTCCCTGA CGCTGGCCAT CGCCCGCGAG 2760

GTGGGTAACT CCCTGCTTAC CGACAGCCTG CTGGCGGAAT CCAACCGTCA CCTCAATCAG 2820

ATGTACGGCC TGCTGGAGAG CATGGACGAT GGGGTGATGG CGTGGAACGA ACAGGGCGTG 2880

CTGCAGTTTC TCAATGTTCA GGCGGCGAGA CTGCTGCATC TTGATGCTCA GGCCAGCCAG 2940

GGGAAAAATA TCGCCGATCT GGTGACCCTC CCGGCGCTGC TGCGCCGCGC CATCAAACAC 3000

GCCCGCGGCC TGAATCACGT CGAAGTCACC TTTGAAAGTC AGCATCAGTT TGTCGATGCG 3060

GTGATCACCT TAAAACCGAT TGTCGAGGCG CAAGGCAACA GTTTTATTCT GCTGCTGCAT 3120

CCGGTGGAGC AGATGCGGCA GCTGATGACC AGCCAGCTCG GTAAAGTCAG CCACACCTTT 3180

GAGCAGATGT CTGCCGACGA TCCGGAAACC CGACGCCTGA TCCACTTTGG CCGCCAGGCG 3240

GCGCGCGGCG GCTTCCCGGT GCTACTGTGC GGCGAAGAGG GGGTCGGGAA AGAGCTGCTG 3300

AGCCAGGCTA TTCACAATGA AAGCGAACGG GCGGGCGGCC CCTACATCTC CGTCAACTGC 3360

CAGCTATATG CCGACAGCGT GCTGGGCCAG GACTTTATGG GCAGCGCCCC TACCGACGAT 3420

GAAAATGGTC GCCTGAGCCG CCTTGAGCTG GCCAACGGCG GCACCCTGTT TCTGGAAAAG 3480

ATCGAGTATC TGGCGCCGGA GCTGCAGTCG GCTCTGCTGC AGGTGATTAA GCAGGGCGTG 3540

CTCACCCGCC TCGACGCCCG GCGCCTGATC CCGGTGGATG TGAAGGTGAT TGCCACCACC 3600

ACCGTCGATC TGGCCAATCT GGTGGAACAG AACCGCTTTA GCCGCCAGCT GTACTATGCG 3660

CTGCACTCCT TTGAGATCGT CATCCCGCCG CTGCGCGCCC GACGCAACAG TATTCCGTCG 3720

CTGGTGCATA ACCGGTTGAA GAGCCTGGAG AAGCGTTTCT CTTCGCGACT GAAAGTGGAC 3780

GATGACGCGC TGGCACAGCT GGTGGCCTAC TCGTGGCCGG GGAATGATTT TGAGCTCAAC 3840

AGCGTCATTG AGAATATCGC CATCAGCAGC GACAACGGCC ACATTCGCCT GAGTAATCTG 3900

CCGGAATATC TCTTTTCCGA GCGGCCGGGC GGGGATAGCG CGTCATCGCT GCTGCCGGCC 3960

AGCCTGACTT TTAGCGCCAT CGAAAAGGAA GCTATTATTC ACGCCGCCCG GGTGACCAGC 4020

GGGCGGGTGC AGGAGATGTC GCAGCTGCTC AATATCGGCC GCACCACCCT GTGGCGCAAA 4080

ATGAAGCAGT ACGATATTGA CGCCAGCCAG TTCAAGCGCA AGCATCAGGC CTAGTCTCTT 4140

CGATTCGCGC CATGGAGAAC AGGGCATCCG ACAGGCGATT GCTGTAGCGT TTGAGCGCGT 4200

CGCGCAGCGG ATGCGCGCGG TCCATGGCCG TCAGCAGGCG TTCGAGCCGA CGGGACTGGG 4260

TGCGCGCCAC GTGCAGCTGG GCAGAGGCGA GATTCCTCCC CGGGATCACG AACTGTTTTA 4320

ACGGGCCGCT CTCGGCCATA TTGCGGTCGA TAAGCCGCTC CAGGGCGGTG ATCTCCTCTT 4380

CGCCGATCGT CTGGCTCAGG CGGGTCAGGC CCCGCGCATC GCTGGCCAGT TCAGCCCCCA 4440

GCACGAACAG CGTCTGCTGA ATATGGTGCA GGCTTTCCCG CAGCCCGGCG TCGCGGGTCG 4500

TGGCGTAGCA GACGCCCAGC TGGGATATCA GTTCATCGAC GGTGCCGTAG GCCTCGACGC 4560

GAATATGGTC TTTCTCGATG CGGCTGCCGC CGTACAGGGC GGTGGTGCCT TTATCCCCGG 4620

TGCGGGTATA GATACGATAC ATTCAGTTTC TCTCACTTAA CGGCAGGACT TTAACCAGCT 4680

GCCCGGCGTT GGCGCCGAGC GTACGCAGTT GATCGTCGCT ATCGGTGACG TGTCCGGTAG 4740

CCAGCGGCGC GTCCGCCGGC AGCTGGGCAT GAGTGAGGGC TATCTCGCCG GACGCGCTGA 4800

GCCCGATACC CACCCGCAGG GGCGAGCTTC TGGCCGCCAG GGCGCCCAGC GCAGCGGCGT 4860

CACCGCCTCC GTCATAGGTT ATGGTCTGGC AGGGGACCCC CTGCTCCTCC AGCCCCCAGC 4920

ACAGCTCATT GATGGCGCCG GCATGGTGCC CGCGCGGATC GTAAAACAGG CGTACGCCTG 4980

GCGGTGAAAG CGACATGACG GTCCCCTCGT TAACACTCAG AATGCCTGGC GGAAAATCGC 5040

GGCAATCTCC TGCTCGTTGC CTTTACGCGG GTTCGAGAAC GCATTGCCGT CTTTTAGAGC 5100

CATCTCCGCC ATGTAGGGGA AGTCGGCCTC TTTTACCCCC AGATCGCGCA GATGCTGCGG 5160

AATACCGATA TCCATCGACA GACGCGTGAT AGCGGCGATG GCTTTTTCCG CCGCGTCGAG 5220

AGTGGACAGT CCGGTGATAT TTTCGCCCAT CAGTTCAGCG ATATCGGCGA ATTTCTCCGG 5280

GTTGGCGATC AGGTTGTAGC GCGCCACATG CGGCAGCAGG ACAGCGTTGG CCACGCCGTG 5340

CGGCATGTCG TACAGGCCGC CCAGCTGGTG CGCCATGGCG TGCACGTAGC CGAGGTTGGC 5400

GTTATTGAAA GCCATCCCGG CCAGCAGAGA AGCATAGGCC ATGTTTTCCC GCGCCTGCAG 5460

ATTGCTGCCG AGGGCCACGG CCTGGCGCAG GTTGCGGGCG ATGAGGCGGA TCGCCTGCAT 5520

GGCGGCGGCG TCCGTCACCG GGTTAGCGTC TTTGGAGATA TAGGCCTCTA CGGCGTGGGT 5580

CAGGGCATCC ATCCCGGTCG CCGCGGTCAG GGCGGCCGGT TTACCGATCA TCAGCAGTGG 5640

ATCGTTGATA GAGACCGACG GCAGTTTGCG CCAGCTGACG ATCACAAACT TCACTTTGGT 5700

TTCGGTGTTG GTCAGGACGC AGTGGCGGGT GACCTCGCTG GCGGTGCCGG CGGTGGTATT 5760

GACCGCGACG ATAGGCGGCA GCGGGTTGGT CAGGGTCTCG ATTCCGGCAT ACTGGTACAG 5820

ATCGCCCTCA TGGGTGGCGG CGATGCCGAT GCCTTTGCCG CAATCGTGCG GGCTGCCGCC 5880

GCCCACGGTG ACGATGATGT CGCACTGTTC GCGGCGAAAC ACGGCGAGGC CGTCGCGCAC 5940

GTTGGTGTCT TTCGGGTTCG GCTCGACGCC GTCAAAGATC GCCACCTCGA TCCCGGCCTC 6000

CCGCAGATAA TGCAGGGTTT TGTCCACCGC GCCATCTTTA ATTGCCCGCA GGCCTTTGTC 6060

GGTGACCAGC AGGGCTTTTT TCCCCCCCAG CAGCTGGCAG CGTTCGCCGA CTACGGAAAT 6120

GGCGTTGGGG CCAAAAAAGT TAACGTTTGG CACCAGATAA TCAAACATAC GATAGCTCAT 6180

AATATACCTT CTCGCTTCAG GTTATAATGC GGAAAAACAA TCCAGGGCGC ACTGGGCTAA 6240

TAATTGATCC TGCTCGACCG TACCGCCGCT AACGCCGACG GCGCCAATTA CCTGCTCATT 6300

AAAAATAACT GGCAGGCCGC CGCCAAAAAT AATAATTCGC TGTTGGTTGG TTAGCTGCAG 6360

ACCGTACAGA GATTGTCCTG GCTGGACCGC TGACGTAATT TCATGGGTAC CTTGCTTCAG 6420

GCTGCAGGCG CTCCAGGCTT TATTCAGGGA AATATCGCAG CTGGAGACGA AGGCCTCGTC 6480

CATCCGCTGG ATAAGCAGCG TGTTGCCTCC GCGGTCAACT ACGGAAAACA CCACCGCCAC 6540

GTTGATCTCA GTGGCTTTTT TTTCCACCGC CGCCGCCATT TGCTGGGCGG CGGCCAGGGT 6600

GATTGTCTGA ACTTGTTGGC TCTTGTTCAT CATTCTCTCC CGCACCAGGA TAACGCTGGC 6660

GCGAATAGTC AGTAGGGGGC GATAGTAAAA AACTATTACC ATTCGGTTGG CTTGCTTTAT 6720

TTTTGTCAGC GTTATTTTGT CGCCCGCCAT GATTTAGTCA ATAGGGTTAA AATAGCGTCG 6780

AAAAACGTA ATTAAGGGCG TTTTTTATTA ATTGATTTAT ATCATTGCGG GCGATCACAT 6840

TTTTTATTTT TGCCGCCGGA GTAAAGTTTC ATAGTGAAAC TGTCGGTAGA TTTCGTGTGC 6900

CAAATTGAAA CGAAATTAAA TTTATTTTTT TCACCACTGG CTCATTTAAA GTTCCGCTAT 6960

TGCCGGTAAT GGCCGGGCGG CAACGACGCT GGCCCGGCGT ATTCGCTACC GTCTGCGGAT 7020

TTCACCTTTT GAGCCGATGA ACAATGAAAA GATCAAAACG ATTTGCAGTA CTGGCCCAGC 7080

GCCCCGTCAA TCAGGACGGG CTGATTGGCG AGTGGCCTGA AGAGGGGCTG ATCGCCATGG 7140

ACAGCCCCTT TGACCCGGTC TCTTCAGTAA AAGTGGACAA CGGTCTGATC GTCGAACTGG 7200

ACGGCAAACG CCGGGACCAG TTTGACATGA TCGACCGATT TATCGCCGAT TACGCGATCA 7260

ACGTTGAGCG CACAGAGCAG GCAATGCGCC TGGAGGCGGT GGAAATAGCC CGTATGCTGG 7320

TGGATATTCA CGTCAGCCGG GAGGAGATCA TTGCCATCAC TACCGCCATC ACGCCGGCCA 7380

AAGCGGTCGA GGTGATGGCG CAGATGAACG TGGTGGAGAT GATGATGGCG CTGCAGAAGA 7440

TGCGTGCCCG CCGGACCCCC TCCAACCAGT GCCACGTCAC CAATCTCAAA GATAATCCGG 7500

TGCAGATTGC CGCTGACGCC GCCGAGGCCG GGATCCGCGG CTTCTCAGAA CAGGAGACCA 7560

CGGTCGGTAT CGCGCGCTAC GCGCCGTTTA ACGCCCTGGC GCTGTTGGTC GGTTCGCAGT 7620

GCGGCCGCCC CGGCGTGTTG ACGCAGTGCT CGGTGGAAGA GGCCACCGAG CTGGAGCTGG 7680

GCATGCGTGG CTTAACCAGC TACGCCGAGA CGGTGTCGGT CTACGGCACC GAAGCGGTAT 7740

TTACCGACGG CGATGATACG CCGTGGTCAA AGGCGTTCCT CGCCTCGGCC TACGCCTCCC 7800

GCGGGTTGAA AATGCGCTAC ACCTCCGGCA CCGGATCCGA AGCGCTGATG GGCTATTCGG 7860

AGAGCAAGTC GATGCTCTAC CTCGAATCGC GCTGCATCTT CATTACTAAA GGCGCCGGGG 7920

TTCAGGGACT GCAAAACGGC GCGGTGAGCT GTATCGGCAT GACCGGCGCT GTGCCGTCGG 7980

GCATTCGGGC GGTGCTGGCG GAAAACCTGA TCGCCTCTAT GCTCGACCTC GAAGTGGCGT 8040

CCGCCAACGA CCAGACTTTC TCCCACTCGG ATATTCGCCG CACCGCGCGC ACCCTGATGC 8100

AGATGCTGCC GGGCACCGAC TTTATTTTCT CCGGCTACAG CGCGGTGCCG AACTACGACA 8160

ACATGTTCGC CGGCTCGAAC TTCGATGCGG AAGATTTTGA TGATTACAAC ATCCTGCAGC 8220

GTGACCTGAT GGTTGACGGC GGCCTGCGTC CGGTGACCGA GGCGGAAACC ATTGCCATTC 8280

GCCAGAAAGC GGCGCGGGCG ATCCAGGCGG TTTTCCGCGA GCTGGGGCTG CCGCCAATCG 8340

CCGACGAGGA GGTGGAGGCC GCCACCTACG CGCACGGCAG CAACGAGATG CCGCCGCGTA 8400

ACGTGGTGGA GGATCTGAGT GCGGTGGAAG AGATGATGAA GCGCAACATC ACCGGCCTCG 8460

ATATTGTCGG CGCGCTGAGC CGCAGCGGCT TTGAGGATAT CGCCAGCAAT ATTCTCAATA 8520

TGCTGCGCCA GCGGGTCACC GGCGATTACC TGCAGACCTC GGCCATTCTC GATCGGCAGT 8580

TCGAGGTGGT GAGTGCGGTC AACGACATCA ATGACTATCA GGGGCCGGGC ACCGGCTATC 8640

GCATCTCTGC CGAACGCTGG GCGGAGATCA AAAATATTCC GGGCGTGGTT CAGCCCGACA 8700

CCATTGAATA AGGCGGTATT CCTGTGCAAC AGACAACCCA AATTCAGCCC TCTTTTACCC 8760

TGAAAACCCG CGAGGGCGGG GTAGCTTCTG CCGATGAACG CGCCGATGAA GTGGTGATCG 8820

GCGTCGGCCC TGCCTTCGAT AAACACCAGC ATCACACTCT GATCGATATG CCCCATGGCG 8880

CGATCCTCAA AGAGCTGATT GCCGGGGTGG AAGAAGAGGG GCTTCACGCC CGGGTGGTGC 8940

GCATTCTGCG CACGTCCGAC GTCTCCTTTA TGGCCTGGGA TGCGGCCAAC CTGAGCGGCT 9000

CGGGGATCGG CATCGGTATC CAGTCGAAGG GGACCACGGT CATCCATCAG CGCGATCTGC 9060

TGCCGCTCAG CAACCTGGAG CTGTTCTCCC AGGCGCCGCT GCTGACGCTG GAGACCTACC 9120

GGCAGATTGG CAAAAACGCT GCGCGCTATG CGCGCAAAGA GTCACCTTCG CCGGTGCCGG 9180

TGGTGAACGA TCAGATGGTG CGGCCGAAAT TTATGGCCAA AGCCGCGCTA TTTCATATCA 9240

AAGAGACCAA ACATGTGGTG CAGGACGCCG AGCCCGTCAC CCTGCACATC GACTTAGTAA 9300

GGGAGTGACC ATGAGCGAGA AAACCATGCG CGTGCAGGAT TATCCGTTAG CCACCCGCTG 9360

CCCGGAGCAT ATCCTGACGC CTACCGGCAA ACCATTGACC GATATTACCC TCGAGAAGGT 9420

GCTCTCTGGC GAGGTGGGCC CGCAGGATGT GCGGATCTCC CGCCAGACCC TTGAGTACCA 9480

GGCGCAGATT GCCGAGCAGA TGCAGCGCCA TGCGGTGGCG CGCAATTTCC GCCGCGCGGC 9540

GGAGCTTATC GCCATTCCTG ACGAGCGCAT TCTGGCTATC TATAACGCGC TGCGCCCGTT 9600

CCGCTCCTCG CAGGCGGAGC TGCTGGCGAT CGCCGACGAG CTGGAGCACA CCTGGCATGC 9660

GACAGTGAAT GCCGCCTTTG TCCGGGAGTC GGCGGAAGTG TATCAGCAGC GGCATAAGCT 9720

GCGTAAAGGA AGCTAAGCGG AGGTCAGCAT GCCGTTAATA GCCGGGATTG ATATCGGCAA 9780

CGCCACCACC GAGGTGGCGC TGGCGTCCGA CTACCCGCAG GCGAGGGCGT TTGTTGCCAG 9840

CGGGATCGTC GCGACGACGG GCATGAAAGG GACGCGGGAC AATATCGCCG GGACCCTCGC 9900

CGCGCTGGAG CAGGCCCTGG CGAAAACACC GTGGTCGATG AGCGATGTCT CTCGCATCTA 9960

TCTTAACGAA GCCGCGCCGG TGATTGGCGA TGTGGCGATG GAGACCATCA CCGAGACCAT 10020

TATCACCGAA TCGACCATGA TCGGTCATAA CCCGCAGACG CCGGGCGGGG TGGGCGTTGG 10080

CGTGGGGACG ACTATCGCCC TCGGGCGGCT GGCGACGCTG CCGGCGGCGC AGTATGCCGA 10140

GGGGTGGATC GTACTGATTG ACGACGCCGT CGATTTCCTT GACGCCGTGT GGTGGCTCAA 10200

TGAGGCGCTC GACCGGGGGA TCAACGTGGT GGCGGCGATC CTCAAAAAGG ACGACGGCGT 10260

GCTGGTGAAC AACCGCCTGC GTAAAACCCT GCCGGTGGTG GATGAAGTGA CGCTGCTGGA 10320

GCAGGTCCCC GAGGGGGTAA TGGCGGCGGT GGAAGTGGCC GCGCCGGGCC AGGTGGTGCG 10380

GATCCTGTCG AATCCCTACG GGATCGCCAC CTTCTTCGGG CTAAGCCCGG AAGAGACCCA 10440

GGCCATCGTC CCCATCGCCC GCGCCCTGAT TGGCAACCGT TCCGCGGTGG TGCTCAAGAC 10500

CCCGCAGGGG GATGTGCAGT CGCGGGTGAT CCCGGCGGGC AACCTCTACA TTAGCGGCGA 10560

AAAGCGCCGC GGAGAGGCCG ATGTCGCCGA GGGCGCGGAA GCCATCATGC AGGCGATGAG 10620

CGCCTGCGCT CCGGTACGCG ACATCCGCGG CGAACCGGGC ACCCACGCCG GCGGCATGCT 10680

TGAGCGGGTG CGCAAGGTAA TGGCGTCCCT GACCGGCCAT GAGATGAGCG CGATATACAT 10740

CCAGGATCTG CTGGCGGTGG ATACGTTTAT TCCGCGCAAG GTGCAGGGCG GGATGGCCGG 10800

CGAGTGCGCC ATGGAGAATG CCGTCGGGAT GGCGGCGATG GTGAAAGCGG ATCGTCTGCA 10860

AATGCAGGTT ATCGCCCGCG AACTGAGCGC CCGACTGCAG ACCGAGGTGG TGGTGGGCGG 10920

CGTGGAGGCC AACATGGCCA TCGCCGGGGC GTTAACCACT CCCGGCTGTG CGGCGCCGCT 10980

GGCGATCCTC GACCTCGGCG CCGGCTCGAC GGATGCGGCG ATCGTCAACG CGGAGGGGCA 11040

GATAACGGCG GTCCATCTCG CCGGGGCGGG GAATATGGTC AGCCTGTTGA TTAAAACCGA 11100

GCTGGGCCTC GAGGATCTTT CGCTGGCGGA AGCGATAAAA AAATACCCGC TGGCCAAAGT 11160

GGAAAGCCTG TTCAGTATTC GTCACGAGAA TGGCGCGGTG GAGTTCTTTC GGGAAGCCCT 11220

CAGCCCGGCG GTGTTCGCCA AAGTGGTGTA CATCAAGGAG GGCGAACTGG TGCCGATCGA 11280

TAACGCCAGC CCGCTGGAAA AAATTCGTCT CGTGCGCCGG CAGGCGAAAG AGAAAGTGTT 11340

TGTCACCAAC TGCCTGCGCG CGCTGCGCCA GGTCTCACCC GGCGGTTCCA TTCGCGATAT 11400

CGCCTTTGTG GTGCTGGTGG GCGGCTCATC GCTGGACTTT GAGATCCCGC AGCTTATCAC 11460

GGAAGCCTTG TCGCACTATG GCGTGGTCGC CGGGCAGGGC AATATTCGGG GAACAGAAGG 11520

GCCGCGCAAT GCGGTCGCCA CCGGGCTGCT ACTGGCCGGT CAGGCGAATT AAACGGGCGC 11580

TCGCGCCAGC CTCTCTCTTT AACGTGCTAT TTCAGGATGC CGATAATGAA CCAGACTTCT 11640

ACCTTAACCG GGCAGTGCGT GGCCGAGTTT CTTGGCACCG GATTGCTCAT TTTCTTCGGC 11700

GCGGGCTGCG TCGCTGCGCT GCGGGTCGCC GGGGCCAGCT TTGGTCAGTG GGAGATCAGT 11760

ATTATCTGGG GCCTTGGCGT CGCCATGGCC ATCTACCTGA CGGCCGGTGT CTCCGGCGCG 11820

CACCTAAATC CGGCGGTGAC CATTGCCCTG TGGCTGTTCG CCTGTTTTGA ACGCCGCAAG 11880

GTGCTGCCGT TTATTGTTGC CCAGACGGCC GGGGCCTTCT GCGCCGCCGC GCTGGTGTAT 11940

GGGCTCTATC GCCAGCTGTT TCTCGATCTT GAACAGAGTC AGCATATCGT GCGCGGCACT 12000

GCCGCCAGTC TTAACCTGGC CGGGGTCTTT TCCACGTACC CGCATCCACA TATCACTTTT 12060

ATACAAGCGT TTGCCGTGGA GACCACCATC ACGGCAATCC TGATGGCGAT GATCATGGCC 12120

CTGACCGACG ACGGCAACGG AATTC 12145

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 94 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AGCTTAGGAG TCTAGAATAT TGAGCTCGAA TTCCCGGGCA TGCGGTACCG GATCCAGAAA 60

AAAGCCCGCA CCTGACAGTG CGGGCTTTTT TTTT 94

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PRIMER"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GGAATTCAGA TCTCAGCAAT GAGCGAGAAA ACCATGC 37

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PRIMER"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GCTCTAGATT AGCTTCCTTT ACGCAGC 27

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PRIMER"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GGCCAAGCTT AAGGAGGTTA ATTAAATGAA AAG 33

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PRIMER"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GCTCTAGATT ATTCAATGGT GTCGGG 26

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PRIMER"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GCGCCGTCTA GAATTATGAG CTATCGTATG TTTGATTATC TG 42

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PRIMER"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TCTGATACGG GATCCTCAGA ATGCCTGGCG GAAAAT 36

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PRIMER"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

TCTATTGTGG ATGCTTTACC ATGGTTAAAA 30

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PRIMER"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CACCGACGCC GGATCCAAAC ACCAGC 26

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PRIMER"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TCACTGTCGA AGAGGATCCG TAAAATCAAC GCCATGAC 38

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PRIMER"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GGCATTTGGC GGCGAAGCTT TATGGTGGCT ACAC 34

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PRIMER"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

TCGACGAATT CAGGAGGA 18

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PRIMER"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CTAGTCCTCC TGAATTCG 18

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4549 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

AGCTCGTCAG CGGGTGTTGG CGGGTGTCGG GGCTGGCTTA ACTATGCGGC ATCAGAGCAG 60

ATTGTACTGA GAGTGCACCA TATGCGGTGT GAAATACCGC ACAGATGCGT AAGGAGAAAA 120

TACCGCATCA GGCGCCATTC GCCATTCAGG CTGCGCAACT GTTGGGAAGG GCGATCGGTG 180

CGGGCCTCTT CGCTATTACG CCAGCTGGCG AAAGGGGGAT GTGCTGCAAG GCGATTAAGT 240

TGGGTAACGC CAGGGTTTTC CCAGTCACGA CGTTGTAAAA CGACGGCCAG TGAATTCGAG 300

CTCGGTACCC GGGGATCCTC TAGAGTCGAC CTGCAGGCAT GCAAGCTTGG CGTAATCATG 360

GTCATAGCTG TTTCCTGTGT GAAATTGTTA TCCGCTCACA ATTCCACACA ACATACGAGC 420

CGGAAGCATA AAGTGTAAAG CCTGGGGTGC CTAATGAGTG AGCTAACTCA CATTAATTGC 480

GTTGCGCTCA CTGCCCGCTT TCCAGTCGGG AAACCTGTCG TGCCAGCTGC ATTAATGAAT 540

CGGCCAACGC GAATTCCCGA CAGTAAGACG GGTAAGCCTG TTGATGATAC CGCTGCCTTA 600

CTGGGTGCAT TAGCCAGTCT GAATGACCTG TCACGGGATA ATCCGAAGTG GTCAGACTGG 660

AAAATCAGAG GGCAGGAACT GCTGAACAGC AAAAAGTCAG ATAGCACCAC ATAGCAGACC 720

CGCCATAAAA CGCCCTGAGA AGCCCGTGAC GGGCTTTTCT TGTATTATGG GTAGTTTCCT 780

TGCATGAATC CATAAAAGGC GCCTGTAGTG CCATTTACCC CCATTCACTG CCAGAGCCGT 840

GAGCGCAGCG AACTGAATGT CACGAAAAAG ACAGCGACTC AGGTGCCTGA TGGTCGGAGA 900

CAAAAGGAAT ATTCAGCGAT TTGCCCGAGC TTGCGAGGGT GCTACTTAAG CCTTTAGGGT 960

TTTAAGGTCT GTTTTGTAGA GGAGCAAACA GCGTTTGCGA CATCCTTTTG TAATACTGCG 1020

GAACTGACTA AAGTAGTGAG TTATACACAG GGCTGGGATC TATTCTTTTT ATCTTTTTTT 1080

ATTCTTTCTT TATTCTATAA ATTATAACCA CTTGAATATA AACAAAAAAA ACACACAAAG 1140

GTCTAGCGGA ATTTACAGAG GGTCTAGCAG AATTTACAAG TTTTCCAGCA AAGGTCTAGC 1200

AGAATTTACA GATACCCACA ACTCAAAGGA AAAGGACTAG TAATTATCAT TGACTAGCCC 1260

ATCTCAATTG GTATAGTGAT TAAAATCACC TAGACCAATT GAGATGTATG TCTGAATTAG 1320

TTGTTTTCAA AGCAAATGAA CTAGCGATTA GTCGCTATGA CTTAACGGAG CATGAAACCA 1380

AGCTAATTTT ATGCTGTGTG GCACTACTCA ACCCCACGAT TGAAAACCCT ACAAGGAAAG 1440

AACGGACGGT ATCGTTCACT TATAACCAAT ACGCTCAGAT GATGAACATC AGTAGGGAAA 1500

ATGCTTATGG TGTATTAGCT AAAGCAACCA GAGAGCTGAT GACGAGAACT GTGGAAATCA 1560

GGAATCCTTT GGTTAAAGGC TTTGAGATTT TCCAGTGGAC AAACTATGCC AAGTTCTCAA 1620

GCGAAAAATT AGAATTAGTT TTTAGTGAAG AGATATTGCC TTATCTTTTC CAGTTAAAAA 1680

AATTCATAAA ATATAATCTG GAACATGTTA AGTCTTTTGA AAACAAATAC TCTATGAGGA 1740

TTTATGAGTG GTTATTAAAA GAACTAACAC AAAAGAAAAC TCACAAGGCA AATATAGAGA 1800

TTAGCCTTGA TGAATTTAAG TTCATGTTAA TGCTTGAAAA TAACTACCAT GAGTTTAAAA 1860

GGCTTAACCA ATGGGTTTTG AAACCAATAA GTAAAGATTT AAACACTTAC AGCAATATGA 1920

AATTGGTGGT TGATAAGCGA GGCCGCCCGA CTGATACGTT GATTTTCCAA GTTGAACTAG 1980

ATAGACAAAT GGATCTCGTA ACCGAACTTG AGAACAACCA GATAAAAATG AATGGTGACA 2040

AAATACCAAC AACCATTACA TCAGATTCCT ACCTACATAA CGGACTAAGA AAAACACTAC 2100

ACGATGCTTT AACTGCAAAA ATTCAGCTCA CCAGTTTTGA GGCAAAATTT TTGAGTGACA 2160

TGCAAAGTAA GTATGATCTC AATGGTTCGT TCTCATGGCT CACGCAAAAA CAACGAACCA 2220

CACTAGAGAA CATACTGGCT AAATACGGAA GGATCTGAGG TTCTTATGGC TCTTGTATCT 2280

ATCAGTGAAG CATCAAGACT AACAAACAAA AGTAGAACAA CTGTTCACCG TTACATATCA 2340

AAGGGAAAAC TGTCCATATG CACAGATGAA AACGGTGTAA AAAAGATAGA TACATCAGAG 2400

CTTTTACGAG TTTTTGGTGC ATTCAAAGCT GTTCACCATG AACAGATCGA CAATGTAACA 2460

GATGAACAGC ATGTAACACC TAATAGAACA GGTGAAACCA GTAAAACAAA GCAACTAGAA 2520

CATGAAATTG AACACCTGAG ACAACTTGTT ACAGCTCAAC AGTCACACAT AGACAGCCTG 2580

AAACAGGCGA TGCTGCTTAT CGAATCAAAG CTGCCGACAA CACGGGAGCC AGTGACGCCT 2640

CCCGTGGGGA AAAAATCATG GCAATTCTGG AAGAAATAGC GCTTTCAGCC GGCAAACCGG 2700

CTGAAGCCGG ATCTGCGATT CTGATAACAA ACTAGCAACA CCAGAACAGC CCGTTTGCGG 2760

GCAGCAAAAC CCGTGGGAAT TAATTCCCCT GCTCGCGCAG GCTGGGTGCC AAGCTCTCGG 2820

GTAACATCAA GGCCCGATCC TTGGAGCCCT TGCCCTCCCG CACGATGATC GTGCCGTGAT 2880

CGAAATCCAG ATCCTTGACC CGCAGTTGCA AACCCTCACT GATCCGCATG CCCGTTCCAT 2940

ACAGAAGCTG GGCGAACAAA CGATGCTCGC CTTCCAGAAA ACCGAGGATG CGAACCACTT 3000

CATCCGGGGT CAGCACCACC GGCAAGCGCC GCGACGGCCG AGGTCTTCCG ATCTCCTGAA 3060

GCCAGGGCAG ATCCGTGCAC AGCACCTTGC CGTAGAAGAA CAGCAAGGCC GCCAATGCCT 3120

GACGATGCGT GGAGACCGAA ACCTTGCGCT CGTTCGCCAG CCAGGACAGA AATGCCTCGA 3180

CTTCGCTGCT GCCCAAGGTT GCCGGGTGAC GCACACCGTG GAAACGGATG AAGGCACGAA 3240

CCCAGTGGAC ATAAGCCTGT TCGGTTCGTA AGCTGTAATG CAAGTAGCGT ATGCGCTCAC 3300

GCAACTGGTC CAGAACCTTG ACCGAACGCA GCGGTGGTAA CGGCGCAGTG GCGGTTTTCA 3360

TGGCTTGTTA TGACTGTTTT TTTGGGGTAC AGTCTATGCC TCGGGCATCC AAGCAGCAAG 3420

CGCGTTACGC CGTGGGTCGA TGTTTGATGT TATGGAGCAG CAACGATGTT ACGCAGCAGG 3480

GCAGTCGCCC TAAAACAAAG TTAAACATCA TGAGGGAAGC GGTGATCGCC GAAGTATCGA 3540

CTCAACTATC AGAGGTAGTT GGCGTCATCG AGCGCCATCT CGAACCGACG TTGCTGGCCG 3600

TACATTTGTA CGGCTCCGCA GTGGATGGCG GCCTGAAGCC ACACAGTGAT ATTGATTTGC 3660

TGGTTACGGT GACCGTAAGG CTTGATGAAA CAACGCGGCG AGCTTTGATC AACGACCTTT 3720

TGGAAACTTC GGCTTCCCCT GGAGAGAGCG AGATTCTCCG CGCTGTAGAA GTCACCATTG 3780

TTGTGCACGA CGACATCATT CCGTGGCGTT ATCCAGCTAA GCGCGAACTG CAATTTGGAG 3840

AATGGCAGCG CAATGACATT CTTGCAGGTA TCTTCGAGCC AGCCACGATC GACATTGATC 3900

TGGCTATCTT GCTGACAAAA GCAAGAGAAC ATAGCGTTGC CTTGGTAGGT CCAGCGGCGG 3960

AGGAACTCTT TGATCCGGTT CCTGAACAGG ATCTATTTGA GGCGCTAAAT GAAACCTTAA 4020

CGCTATGGAA CTCGCCGCCC GACTGGGCTG GCGATGAGCG AAATGTAGTG CTTACGTTGT 4080

CCCGCATTTG GTACAGCGCA GTAACCGGCA AAATCGCGCC GAAGGATGTC GCTGCCGACT 4140

GGGCAATGGA GCGCCTGCCG GCCCAGTATC AGCCCGTCAT ACTTGAAGCT AGACAGGCTT 4200

ATCTTGGACA AGAAGAAGAT CGCTTGGCCT CGCGCGCAGA TCAGTTGGAA GAATTTGTCC 4260

ACTACGTGAA AGGCGAGATC ACCAAGGTAG TCGGCAAATA ATGTCTAACA ATTCGTTCAA 4320

GCCGACGCCG CTTCGCGGCG CGGCTTAACT CAAGCGTTAG ATGCACTAAG CACATAATTG 4380

CTCACAGCCA AACTATCAGG TCAAGTCTGC TTTTATTATT TTTAAGCGTG CATAATAAGC 4440

CCTACACAAA TTGGGAGATA TATCATGAAA GGCTGGCTTT TTCTTGTTAT CGCAATAGTT 4500

GGCGAAGTAA TCGCAACATC CGCATTAAAA TCTAGCGAGG GCTTTACTA 4549

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 199 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GAATTCACTA GTCGATCTGT GCTGTTTGCC ACGGTATGCA GCACCAGCGC GAGATTATGG 60

GCTCGCACGC TCGACTGTCG GACGGGGGCA CTGGAACGAG AAGTCAGGCG AGCCGTCACG 120

CCCTTGACAA TGCCACATCC TGAGCAAATA ATTCAACCAC TAAACAAATC AACCGCGTTT 180

CCCGGAGGTA ACCAAGCTT 199

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/31, 15/53, 15/55, 15/60, C12P 17/18, C12N 9/04, 9/16, 9/88, 1/21, C07K 14/24 // (C12N 1/21, C12R 1:19)

A3

(11) International Publication Number: **WO 99/58686**

(43) International Publication Date: 18 November 1999 (18.11.99)

(21) International Application Number: PCT/US99/10356

(22) International Filing Date: 12 May 1999 (12.05.99)

(30) Priority Data:
60/085,190 12 May 1998 (12.05.98) US

(71) Applicants *(for all designated States except US)*: E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). GENENCOR INTERNATIONAL, INC. [US/US]; 925 Page Mill Road, Palo Alto, CA 94304–1013 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: WHITED, Gregory, M. [US/US]; 304 South Road, Belmont, CA 94002 (US). BULTHUIS, Ben [NL/NL]; Einsteinweg 101, Postbus 251, NL–2300 AG Leiden (NL). TRIMBUR, Donald, E. [US/US]; 349 Orchard Avenue, Redwood City, CA 94601 (US). GATENBY, Anthony, A. [US/US]; 2309 Baynard Boulevard, Wilmington, DE 19802 (US).

(74) Agent: FLOYD, Linda, Axamethy; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AU, BR, CA, CN, ID, IL, JP, KR, MX, SG, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
9 March 2000 (09.03.00)

(54) Title: METHOD FOR THE PRODUCTION OF 1,3–PROPANEDIOL BY RECOMBINANT ORGANISMS COMPRISING GENES FOR VITAMIN B12 TRANSPORT

(57) Abstract

Recombinant organisms are provided comprising genes encoding genes encoding glycerol dehydratase, 1,3–propanediol oxidoreductase, a gene encoding vitamin B_{12} receptor precursor (BtuB), a gene encoding vitamin B_{12} transport system permease protein (BtuC) and a gene encoding vitamin B_{12} transport ATP–binding protein (BtuD). The recombinant microorganism is contacted with a carbon substrate and 1,3–propanediol is isolated from the growth media.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

INTERNATIONAL SEARCH REPORT

Inter onal Application No
PCT/US 99/10356

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/31 C12N15/53 C12N15/55 C12N15/60 C12N9/04
C12N9/16 C12N9/88 C12N1/21 C07K14/24 C12P7/18
//(C12N1/21,C12R1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C12P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 35795 A (DU PONT ;NAGARAJAN VASANTHA (US); NAKAMURA CHARLES EDWIN (US)) 14 November 1996 (1996-11-14) cited in the application page 18, paragraph 1 ---	1-13
A	FRIEDRICH M J ET AL: "Nucleotide sequence of the btuCED genes involved in vitamin B12 transport in Escherichia coli and homology with components of periplasmic-binding-protein-dependent transport systems." JOURNAL OF BACTERIOLOGY, vol. 167, no. 3, September 1986 (1986-09), pages 928-934, XP000857891 WASHINGTON, DC, US ISSN: 0021-9193 figure 2 --- -/--	1

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
11 January 2000	21/01/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Lejeune, R

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inter ›nal Application No
PCT/US 99/10356

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication.where appropriate. of the relevant passages	Relevant to claim No.
A	CAMERON D C ET AL: "METABOLIC ENGINEERING OF PROPANEDIOL PATHWAYS" BIOTECHNOLOGY PROGRESS, vol. 14, no. 1, 6 February 1998 (1998-02-06), page 116-125 XP002067772 ISSN: 8756-7938 abstract page 119, column 2, paragraph 1 ---	1-13
P,A	WO 98 21339 A (DIAS TORRES MARIA ;HAYNIE SHARON LORETTA (US); HSU AMY KUANG HUA ( ) 22 May 1998 (1998-05-22) abstract page 16 -page 17 -----	8,13

1